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Abstract 
The potential molecular mechanism of resistance of Neisseria gonorrhoeae to 
spectinomycin was investigated using N gonorrhoeae isolates collected between 
2000 and 2004 from patients with male urethritis syndrome in Durban. 
Stored isolates were grown on New York City agar plates. Minimum inhibitory 
concentrations (MIC) to spectinomycin were perfomed by means of agar dilution. 
PCR was performed using primers specific for the aadA gene which codes for a 
spectinomycin inactivating enzyme. A nested PCR was used to amplify the gene 
coding for the spectinomycin target site in the 16S rRNA. PCR was also done to 
amplify the mtrR gene of the mtrRCDE efflux pump since mutations in this gene are 
associated with increased antimicrobial resistance. The products were sequenced to 
detect mutations associated with increasing MICs. 
MICs of the 53 isolates studied ranged from 4 to 64 mg/L. None of the isolates 
contained the aadA gene. The observed increase in MICs to spectinomycin in N 
gonorrhoeae isolates from Durban could therefore not be attributed to the production 
of an antibiotic modifying enzyme. Sequencing of the l 6S rRNA gene did not reveal 
any mutations that could be attributed to the increasing spectinomycin MICs 
observed. Sequencing of the mtrR gene revealed random mutations. However on 
phylogenetic analysis, no correlation could be found with the various MIC levels. The 
mtrRCDE efflux pump cannot be conclusively ruled out as a possibility for the 
increase in MICs but further investigation is needed. 
xv 
The resistance mechanism causing the incremental increase in spectinomycin MICs 




Gonorrhoea is a sexually transmitted infection caused by the organism Neisseria 
gonorrhoeae. It is a common cause of STis (Alary, 1997), with a global estimate of 
62 million new cases in 1999. The burden of infection varies among the different 
regions of the world. Western Europe and the USA reported a decline in the 
prevalence of gonococcal infections from 1980 to 1996 (WHO, 2001). These regions 
of the world are considered to be more developed and the decline in prevalence has 
been attributed to an increased awareness of STis, including HIV (Alary, 1997). 
The prevalence rates of N gonorrhoeae in developing countries during the l 990's 
was reported to be 3.5% in Papua New Guinea, 3% in Cambodia, 1 % in the 
Philippines and 0.5% in Vietnam (WHO, 2001). The African continent carries the 
heaviest burden of gonococcal infection with an estimated 17 million new cases in 
sub-Saharan Africa alone (WHO, 2001). Reports on the prevalence of gonorrhoea in 
Africa varies with rates of 0.02% in Gabon (1999), 5.7% in Benin (1998), 8.4% in 
Tanzania (1998), 7.8% in South Africa (1998), 17.1% in Malawi (1998) (WHO, 
2001) and 0.6% in Ghana (2001) (Apea - Kubi et al., 2004). 
The increase in the prevalence of N gonorrhoeae may be attributed to the high 
prevalence of asymptomatic infection with high infection rates, the lack of effective 
point of care diagnostic tests, as well as the development of resistance to many of the 
recommended antimicrobials for the treatment of this infection (Alary, 1997). 
N gonorrhoeae may be transmitted by sexual contact or vertically from mother to 
child. Patients infected with N gonorrhoeae may be asymptomatic, or may present 
with genital discharge, urethritis, genital itchiness or conjunctivitis. The complications 
arising from this infection are numerous and include infertility, sepsis and sometimes 
death. 
The development of resistance to the various antimicrobials used for the treatment of 
infection with N gonorrhoeae is increasing (Shigemura et al., 2004). Spectinomycin 
is an aminocyclitol antibiotic used to treat most forms of gonorrhoea. This antibiotic 
is administered intramuscularly to patients allergic to P-lactam agents or as an 
alternative to quinolones in pregnant women. (Medline, 1993). 
Spectinomycin works by binding to the 30S ribosomal subunit and preventing the 
transfer of tRNA from the A site to the P site (Vakulenko et al., 2003) thus halting 
protein synthesis, causing organism death. 
Modification of the 16S rRNA of a particular organism can result in resistance to 
spectinomycin (Vakulenko et al., 2003). Resistance can also be mediated by 
enzymatic modification of the antibiotic. The level of resistance depends on many 
factors including the type and strain of micro-organism. High level resistance is most 
commonly mediated by the production of transferases (Vakulenko et al., 2003). 
The aad.A gene, which is present in Gram negative organisms codes for the 
adenyltransferase ANT(3) enzyme which mediates resistance to spectinomycin (Clark 
et al., 1999). aad.A genes are present on extrachromosomal elements and encode 
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adenyltransferases, which modify the position of the 9-OH group in the ring structure 
of spectinomycin (Read, 2000). This results in poor binding of the drug to the 
ribosome which impairs drug activity on the microbe (Vakulenko et al., 2003). The 
aad.A gene also mediates resistance to streptomycin and therefore a certain degree of 
cross resistance may occur between these two drugs. Streptomycin is commonly used 
to treat tuberculosis (TB) and this cross resistance can thus have an effect on the 
treatment of TB. Since STis and TB are amongst the leading infections in South 
Africa, they may often occur together in an individual. The use of spectinomycin in 
dually infection individuals for the treatment of potential infection with N 
gonorrhoeae may lead to the inadvertent treatment of tuberculosis with one agent 
only. 
Although the aadA gene is responsible for resistance to spectinomycin in many 
species including E. coli, it is yet to be proven to be the reason for the increase in 
spectinomycin resistance in N gonorrhoeae. Thus far the aforementioned increase in 
resistance has been attributed to a single step mutation in the 30S ribosomal subunit of 
N gonorrhoeae, which alters the sensitivity of the ribosome to the drug, resulting in 
high level resistance to spectinomycin. This is essentially a chromosomally mediated 
resistance (Johnson and Morse, 1988; Tapsall, 2001). Studies carried out by Johnson 
and Morse (1988) and Maness et al (1974) concluded that the resistance to 
spectinomycin in N gonorrhoeae was not related to antibiotic inactivating enzymes. 
Tapsall (2001), however, did suggest that it was possible for the gonococcus to 
acquire plasmid borne genes encoding resistance via inactivating enzymes. 
Another possible resistance mechanism is the mtrRCDE efflux pump. This multidrug 
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efflux pump is known to be present in all N gonorrhoeae isolates but is yet to be 
linked to spectinomycin resistance. This mtr (multiple transferable resistance) system 
consists of a transcriptional regulator (MtrR) and 3 linked genes viz. mtrC, mtrD and 
mtrE (Hagman et al., 1995). This efflux pump, like most is located in the cytoplasmic 
membrane of organisms and is responsible for the energy dependent extrusion of a 
diverse range of hydrophobic agents (HA) including antibiotics CV eal et al., 1998). 
The mtrRCDE efflux pump belongs to the resistance nodulation and cell division 
(RND) family of efflux pumps and therefore uses proton motive force to drive the 
active efflux of various agents (Grkovic et al., 2002). According to Veal et al (1998) 
the MtrR protein is a repressor which regulates the transcription of the mtrCDE gene 
complex. Mutations in the mtrR gene which codes for the MtrR protein result in a 
decrease of the repressor function of this protein and therefore the expression of the 
mtrC, mtrD and mtrE genes is increased (Hagman et al., 1995), causing enhanced 
activity of the mtrCDE complex which results in higher levels of resistance due to the 
increased rate of extrusion of HAs (Grkovic et al., 2002). 
Prior to the emergence of penicillinase producing N gonorrhoeae (PPNG), penicillin 
was the drug of choice for the treatment of gonorrhoea, while spectinomycin was 
utilised as a second line agent (WHO, 2001 ). This high level resistance to penicillin is 
approximately 33% in KwaZulu Natal (KZN) (Moodley et al., 2001). The initial cases 
of spectinomycin resistance in N gonorrhoeae were recorded in the Far East during 
the 1980's. Treatment failures with spectinomycin have also been noted and are most 
likely to be as a result of the antibiotic being poorly distributed from the injection site 
(Tapsall, 2001). 
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With the syndromic management approach being widely used to treat STis in South 
Africa, another drug that is commonly used against N gonorrhoeae is tetracycline. As 
with penicillin, however, high level resistance (MIC?: 16 mg/L) has also developed 
against tetracycline. The prevalence of high level tetracycline resistant N 
gonorrhoeae in KZN is around 70%. Quinolones have also been used to treat 
gonorrhoea but the prevalence of resistance to ciprofloxacin in KZN has been 
reported to be around 42%. Isolates are still susceptible to the cephalosporins, 
ceftriaxone and cefixime which are used as second line agents against gonorrhoea 
during pregnancy, in South Africa (personal correspondence). Spectinomycin is thus 
an alternative treatment in our country but the MICs of this drug have been 
increasing. 
Table 1.1 shows the trend of MICs to spectinomycin over a 9 year period in KZN 
(Moodley et al., 2006). The minimum inhibitory concentration (MIC) of an organism 
is defined as the lowest concentration of a particular drug that will inhibit the growth 
of the organism. The breakpoint for susceptibility of spectinomycin in N 
gonorrhoeae is 32 mg/L while the breakpoint for resistance is 2'.. 128 mg/L. Table 1. 1 
shows that there is a definite shift to the right of MICs from 1997 to 2003. By 2003, 
93% of isolates had an MIC of 16 mg/L as compared to 8% in 1997. The MICs for 
ciprofloxacin and ceftriaxone also show a shift to the right (Moodley et al., 2006). 
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Table 1.1 : MIC trends of N gonorrhoeae m South Africa from 1995 to 2003 
(Moodley et al., 2006) 
Antimicrobial Agent Year Percentage of Isolates With Minimwn Inhibitory Concentration (mglL) 
� 0.007 / 0.015 I 0.03 I 0.06 I 0.125 I 0.25 I 0.5 I 1 I 2 I 4 I 8 I 16 I 
95 Not Tested 
97 9 3 4 4 5 1 2 7 13 10 17 20 8 
Spectinomycin 98/99 3 2 7 2 6 16 10 48 2 
99/00 22 78 
03 1 93 
95 100 
97 96 4 
Ciprofloxacin 98/99 84 3 9 4 
99/00 71 19 10 
03 75 1 1 1 2 7 12 1 
95 100 
97 95 3 1 2 
Cefuiaxone 98/99 62 26 7 5 
99/00 53 31 10 5 
03 6 38 41 12 1 1 l 
Options for the treatment of gonorrhoea are declining while the prevalence of the 
infection appears to be on the increase. Infection with N gonorrhoeae, is treatable but 
this pathogen is developing resistance to recommended antimicrobial agents at a rapid 
rate. This is the case with most first line agents and even with some alternative agents, 
like spectinomycin. It is therefore important to study and understand the mechanisms 
via which spectinomycin resistance is mediated in N gonorrhoeae in order to develop 
more effective drugs for the treatment of this infection. 
Hence, the aim of this investigation was to ascertain the mechanism via which 






Review of Literature 
2.1 Resistance Mechanisms to Antimicrobial Agents 
Bacterial resistance to antimicrobial agents may occur through mutations or via 
plasmid and transposon specified genes (Bryan, 1988). Both these chromosomal and 
extra-chromosomal mechanisms may co-exist in one organism, thereby exponentially 
raising the level of resistance to an antibiotic (Tapsall, 2001 ). In order for an 
antimicrobial agent to carry out its function, it has to be able to enter the cell and then 
attach to and inactivate target sites (Conte Jr. and Barriere, 1992). It is usually at these 
target sites and/ or entry sites that mechanisms of resistance develop. 
According to Li et al (2000), the development of resistance and reduced susceptibility 
of N gonorrhoeae to antimicrobial agents can be attributed to chromosomal 
mutations. Each mutant gene has the ability to increase resistance to a particular 
antibiotic until treatment failure occurs. The resistance genes can be transferred from 
resistant to susceptible strains of an organism (Hu et al., 2005). 
Resistance to bacteria can either be intrinsic or acquired. Intrinsic resistance refers to 
bacteria that are naturally insensitive to an antibiotic without acquiring resistance 
factors (Bryan, 1988). Acquired resistance would therefore refer to the acquisition of 
resistance factors in the form of chromosomal mutations, extra-chromosomal 
resistance genes via plasmids, transposons, integrons, gene cassettes and insertion 
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sequences (Powell, 2000). The most common mechanisms via which acquired 
resistance may occur include alteration of the target site which results in inhibition of 
the binding of the drug, inhibition of transport of the drug into the cell, destruction or 
inactivation of the antibiotic and metabolic bypass where the organism replaces the 
metabolic step inhibited by the antimicrobial agent (Conte Jr. and Barriere, 1992). 
2.1.1 Target Alteration 
This mechanism of resistance occurs when the target site in the cell is altered so that it 
is insensitive to the antimicrobial agent, yet the cell is still able to function normally 
(Gale et al., 1981). According to Conte Jr. and Barriere (1992), this type of resistance 
is commonly associated with antibiotics that interfere with ribosomal function eg: 
streptomycin, spectinomycin and rifampicin. Resistance is thought to originate from 
the selection of pre-existing mutations in a sensitive population of bacteria (Conte Jr. 
and Barriere, 1992). 
Often, the mutations that lead to resistance occur as a result of a single amino acid 
alteration at the target site thereby inhibiting binding of the antibiotic (Powell, 2000). 
In sensitive bacteria, streptomycin binds to protein S 12 in the 30S ribosomal subunit 
of the organism but a single mutation in the polypeptide chain of this protein results in 
decreased affinity with subsequent resistance of the organism to the drug (Conte Jr. 
and Barriere, 1992). Resistance to spectinomycin in N gonorrhoeae is mediated in a 
similar manner. 
Mutations causing a decreased affinity in penicillin-binding protein (PBP) 2 to certain 
penicillins also results in resistance to these agents (Gale et al., 1981 ). 
8 
2.1.2 Enzyme Inactivation of the Drug 
Many bacteria produce enzymes that inactivate antimicrobial agents (Gale et al., 
1981 ). This can be done via enzyme cleavage or alteration of the drug so that it can no 
longer interact with the specified target (Powell, 2000). Aminoglycosides, 
cephalosporins and penicillins are among the antimicrobial agents that can be 
modified by enzymes, making this mechanism of resistance one of great clinical 
importance since these antimicrobial agents are widely used to treat a variety of 
infections (Conte Jr. and Barriere, 1992). 
The genes that code for these modifying enzymes are located on plasmids and are 
therefore completely transferable. The enzymes produced include /J - lactamases and 
cephalosporinases, which inhibit the action of /J -lactam antibiotics. The 
acetyltransferases modify antibiotics via acetylation. Gram positive organisms encode 
a bifunctional aminoglycoside modifying enzyme that inactivates the antibiotic by the 
production of both acetyl- and phosphotransferases (Powell, 2000). 
A number of organisms, including E. coli are resistant to spectinomycin via an 
antibiotic modifying enzyme. The aad.A gene codes for an adenyltransferase that 
modifies the position of the 9-0H in the ring structure of spectinomycin resulting in 
the drug binding poorly to its target site (Read, 2000). 
2.1.3 Synthesis of Resistant Metabolic Pathways 
Certain antimicrobial agents such as trimethoprim work by inhibiting certain enzymes 
in the metabolic pathways of bacteria. Some bacteria, however, are capable of 
producing excess amounts of the enzyme in question so that the metabolic pathway 
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can still function in the presence of the antibiotic, despite its action. Some thymidine­
dependent streptococci produce excess amounts ofthymidine by an alternate pathway, 
so that trimethoprim and sulphonamides have a reduced or no effect (Powell, 2000). 
2.1.4 Failure to Metabolise the Drug 
Some drugs are only activated once they enter the bacterial cell. Failure to metabolise 
the drug means that it remains inactive and the organism becomes resistant, as is the 
case with Bacteriodes fragilis and metronidazole (Powell, 2000). 
2.1.5 Movement of Resistance Genes 
If genes encoding for resistance in bacteria do not occur as part of the bacterial 
chromosome, they may be found on extrachromosomal elements e.g.: plasmids (Gale 
et al., 1981). 
When exposed to adverse conditions bacteria may replicate and exchange genes that 
will confer a selective advantage. The most common genetic exchange mechanisms 
include exchange of plasmids via conjugation. Conjugation involves the direct contact 
of two cells via a sex pilus through which DNA passes unidirectionally from the 
donor cell to the recipient cell (Conte Jr. and Barriere, 1992). 
Transposons or 'jumping genes" commonly allow for the movement of genes 
between the chromosome and the plasmid and vice-versa, although genetic exchange 
via plasmids can occur in the absence of transposons. This exchange is even possible 
between organisms of different genera. Integrons are a subset of transposons often 
found on resistance (R) plasmids. Integrons consist of a "cassette" that codes for 
various functions including antimicrobial resistance, flanked by two conserved 
segments (Powell, 2000). 
Transformation, transduction and conjugation are the three most common methods for 
exchange of genetic information. Transformation involves the lysing of the bacterial 
cell so that the DNA is released into the surrounding medium to be taken up by other 
intact bacteria in the area. Transduction deals with the incorporation of bacterial DNA 
into a bacteriophage, which acts as a vector (Conte Jr. and Barriere, 1992). 
2.1.6 Decrease of Concentration of the Drug 
A decrease in the concentration of an antimicrobial agent at its target site can either be 
as a result of a decrease in the permeability of the cell envelope to the drug so that 
lower concentrations of the drug enter the cell or via an increase in the efflux pwnps 
which pump that drug out of the cell (Conte Jr. and Barriere, 1992; Powell, 2000). 
Resistance seems to be attributed to the fact that critical concentrations of the 
antibiotic cannot be accumulated within the cell (Gale et al., 1981 ). This seems to be 
the case with aminoglycosides and tetracyclines where interference with the transport 
of these antibiotics into the cell is a cause ofresistance in certain organisms (Conte Jr. 
and Barriere, 1992). 
Tetracycline 1s taken up, into normal cells via active transport and therefore 
accumulates within the cell (Conte Jr. and Barriere, 1992). The presence of 
tetracycline in a cell results in changes in the cell membrane that cause tetracycline to 
be excluded from inside the cell, thereby resulting in resistance to the antibiotic. A 
similar mechanism of resistance exists in Gram positive Staphylococcus aureus to 
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fusidic acid where changes in the cell envelope prevent the antibiotic from reaching 
its intended target (Gale et al., 1981 ). 
Another mechanism via which organisms decrease the concentration of the drug 
reaching its target site is via drug efflux pumps. These efflux systems are 
chromosomally encoded and are responsible for the extrusion of toxic substances 
from the cell. Because of their ability to cause drug resistance, these efflux pumps are 
present in many organisms and their gene sequences are conserved in some. Efflux 
pumps have been divided into four major families on the basis of assembly, 
mechanism and sequence homology (Powell, 2000). 
In the ATP binding cassette (ABC) superfamily, each family works on a specific 
substrate including small molecules as well as proteins and carbohydrates produced in 
the cytoplasm. The major facilitator (MF) superfamily consists of more than three 
hundred families, each of which is specific for a different type of solute including 
sugars and organic and inorganic anions. Most drug resistance pumps belong to this 
family. The small multidrug resistance (SMR) family is comprised of only ten 
members, which extrude lipophilic cations. The sequences of these pumps are well 
conserved. Finally, the resistance-nodulation-cell division (RND) family is divided 
into three sub-families, the first is specific for divalent heavy metal ions, the second 
for lipooligosaccharides and the third for the efflux of a number of drugs (Powell, 
2000). 
2.1.6.1 The mtrRCDE Efflux Pump of N. gonorrhoeae 
Efflux pumps can cause resistance to antibiotics as a result of their ability to extrude 
certain agents from the organisms in which they are present. These pumps may be 
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specific to a particular compound or may have the ability to extrude a diverse range of 
compounds, leading to multiple drug resistance (MDR). Efflux systems are usually 
energy dependent and are essentially transport proteins which facilitate the active 
pumping of toxic compounds out of the cell and into the surrounding environment. 
They exist in both Gram positive and Gram negative organisms (Webber and 
Piddock, 2003). 
Gram negative bacteria are known to possess a cytoplasmic membrane as well as an 
outer membrane (OM) and sandwiched in between these 2 membranes is the 
periplasm. Efflux pumps are located in the cytoplasmic membranes of organisms. In 
the case of Gram negative organisms like N gonorrhoeae, the presence of an 
accessory protein is required as part of the efflux system to bridge the gap between 
the cytoplasmic membrane and the OM so that the antibiotics are pumped out of the 
cell completely and not trapped in the periplasm once they have been extruded from 
the cytoplasm (Nikaido, 1994). It is for this reason that the RND family of efflux 
systems to which the mtrRCDE pump belongs consists of 3 proteins working 
synergistically to actively pump substances out of the organism and into the 
surrounding environment, similarly to the MexXY-OprM and MexJK-OprM efflux 
systems found in Pseudomonas aeruginosa (Schweizer, 2003). 
Generally, efflux pumps in Gram negative organisms are thought to consist of a 
tripartite structure (Schweizer, 2003). Figure 2.1 illustrates this general structure. The 
three proteins which constitute this pump are a cytoplasmic membrane associated 
efflux transporter protein that is usually from the MF or RND families, this is attached 
13 
to an accessory protein which is in turn associated with an OM channel protein to 














Figure 2.1 : General Structure of Efflux Systems in Gram Negative Organisms (Modified from 
Nikaido, 1994) 
The mtrRCDE efflux pump of N gonorrhoeae has a similar structure. The MtrD 
protein acts as the efflux transporter protein and belongs to the RND family, the MtrE 
protein is the OM channel protein and the MtrC protein is the accessory protein from 
the MF family (Veal et al., 1998) that joins the MtrD and MtrE proteins (Rouquette­
Loughlin et al., 2002). It can therefore be assumed that the mtrRCDE efflux pump 
executes it function by the HA being captured by the MtrD protein in the cytoplasmic 
membrane, it is subsequently pumped through the MtrC protein and out of the 
organism via the MtrE protein (Nikaido, 1994). 
The MtrR protein is also a significant component of the mtrRCDE efflux pump. It is 
encoded for by the mtrR gene which is situated 250 bp upstream and divergently 
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transcribed from the mtrCDE complex. MtrR is a transcriptional repressor that 
regulates the transcription of the mtrCDE efflux system (Veal et al., 1998). This 
protein is similar to a variety of transcriptional repressors especially those of the TetR 
family (Hagman et al., 1995). According to Grkovic et al (2002), MtrR is only a 
modulator and does not play a role in induction of mtrCDE expression. Although this 
is the case, mutations in the coding or promoter regions of the mtrR gene can result in 
a decrease in MtrR activity. Even a single base pair deletion in the promoter region of 
this gene can cause a reduction in repression of transcription of the mtrCDE complex 
(Veal et al., 1998). This in tum results in increased expression of the mtrCDE genes, 
leading to increases in resistance to HAs as a consequence of higher efflux rates 
(Grkovic et al., 2002). The level of resistance inferred by these pumps can differ 
depending on the type of mutation, for example, organisms which carry mutations in 
the mtrR transcriptional regulator display lower levels ofresistance when compared to 
organisms with mutations in the mtrR promoter region (Hu et al., 2005). 
Mutations in the mtrR gene have been linked to increases in resistance in N 
gonorrhoeae to azithromycin, erythromycin (Grkovic et al., 2002), penicillin and 
tetracycline (Veal et al., 2002). It is therefore possible that spectinomycin resistance 
may also be linked to this efflux pump. 
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2.2 General Characteristics of Neisseria gonorrhoeae 
2.2.1 History of N. gonorrhoeae 
Gonorrhoea is a very old infectious disease that was first identified and described by 
A. Neisser in 1879 (Matsuoka, 1989; Todar, 2004). Subsequently Neisseria
gonorrhoeae was cultured by Bumm in 1885 fulfilling all of Koch's postulates for 
this organism (Matsuoka, 1989; Todar, 2004). 
The infection was named gonorrhoea by Galen in the second century AD as a 
description of the urethral discharge that it caused which was thought to be seminal 
discharge (Oates and Csonka, 1990). 
According to Cheng (1989), gonorrhoea is the most ubiquitous disease of mankind. 
2.2.2 Description 
Neisseria gonorrhoeae is one member of the genus Neisseria as well as the causative 
agent of gonorrhoea. The organism is a non-motile, Gram negative, aerobic 
diplococcus often referred to as the gonococcus. N gonorrhoeae, most commonly 
occurs in pairs of kidney or bean shaped organisms (Cheng, 1989) with adjacent 
flattened sides (Todar, 2004). 
2.2.3 Culture Characteristics of N. gonorrhoeae 
As with most causes of sexually transmitted infections, N gonorrhoeae is difficult to 
culture and requires specialised nutrients and specific conditions to grow (Conte Jr. 
and Barriere, 1992). Many variations and combinations of media have been developed 
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in an effort to optimise the growth of these organisms, for example Thayer-Martin 
(TM) Medium, Martin-Lewis Medium and New York City (NYC) Medium 
(Robertson et al., 1989). 
N gonorrhoeae requires 3 - 10% CO2 to grow at a temperature of 35 - 3 7
°C, for 24 -
48 hours (Oates and Csonka, 1990; Todar, 2004) in a moist environment. These 
conditions also have to be maintained if N gonorrhoeae specimens are to be 
transported, in order to avoid loss of viability of the organism. Media such as Stuarts 
Medium or A.mies Medium are commercially available for the transport of N 
gonorrhoeae and contain the appropriate nutrients to keep the organism viable 
(Robertson et al., 1989) GC transport medium and Charcoal medium are also suitable 
for this purpose. 
2.2.4 Identification Tests for Neisseria gonorrhoeae 
A number of identification tests exist for the gonococcus but the most common 
include colony morphology, Gram staining, the oxidase test as well as carbohydrate 
utilisation tests. 
2.2.4.1 Colony Morphology 
The specimen/s should be streaked onto New York City agar plates and incubated at 
3 7°C, in 3 - 10% CO2 for 24 hours. After the incubation period colonies of N 
gonorrhoeae should appear on the agar plates ( except in the case of slow growing 
strains which may take up to 48 hours to grow). The colonies should be about 0.5 -
1.0 mm in diameter. They should appear glistening and raised as well as opaque and 
gray to white in colour (Morello and Bohnhoff, 1980). 
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2.2.4.2 Gram Stain 
A smear of the specimen is made onto a glass slide, heat fixed using a Bunsen burner 
and subsequently stained using the standard Grams' staining technique. The slide 
should then be viewed under a microscope at I OOOX magnification with 2 mm oil 
immersion (Oates and Csonka, 1990). N. gonorrhoeae is a Gram negative organism 
and therefore appears reddish-pink on a Gram stained smear (figure 2.2). The 




Figure 2.2. : N. gono"hoeae organisms within polymorphonuclear leucocytes 
2.2.4.3 Oxidase Test 
Leucocyte 
This test is part of the battery of tests used in the identification of N. gonorrhoeae. It 
is positive in N. gonorrhoeae. The oxidase test is usually carried out on filter paper or 
on the agar plate on which the culture is growing. A drop of oxidase reagent, 
tetramethyl-p-phenylene-diamine dihydrochloride is added directly to the colony and 
the reaction is read after l 5 to 20 seconds. A positive reaction causes a colour change 
in the reagent from colourless to purple (Morello and Bohnhoff, 1980). 
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2.2.4.4 Carbohydrate Utilisation Test 
N gonorrhoeae can also be identified by its ability to ferment glucose only. This is a 
characteristic unique to N gonorrhoeae while most other Neisseria species ferment 
maltose with or without additional lactose and sucrose fermentation. (Whittington et 
al., 1994) (table 2.1). According to Oates and Csonka (1990), this feature can be 
regarded as the most reliable for the identification of N gonorrhoeae. 
Table 2.1 : Fermentation reactions of Neisseria species (Oates and Csonka (1990)) 
Glucose Maltose Sucrose Lactose 
N gonorrhoeae + - - -
N meningitides + + - -
N pharyngis sicca + + + -
N lactamica + + - + 
2.3 Epidemiology of Neisseria gonorrhoeae Infection 
Neisseria gonorrhoeae is one of the most prevalent sexually transmitted pathogens in 
the world. Gonococcal infection rates have fluctuated over the years. (Todar, 2004). 
Whilst the prevalence rates of gonococcal infections had declined in developed 
countries during the 1980s, the prevalence in Africa was estimated as being between 
5 to 50 times higher than that of the USA. (Cheng 1989). Prevalence studies 
conducted in Africa, Latin America and Asia have also reported that the highest 
prevalence of gonorrhoea was found in Africa (Salam et al., 2005). 
As a result of inadequate diagnostic and treatment options in resource poor settings, 
the prevalence of the STI tends to be higher (Alary, 1997). Moodley et al (2002a) 
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attributed the high prevalence of STis in KwaZulu Natal in South Africa to rapid re­
infection following appropriate syndromic treatment (Moodley, 2002a). 
In Africa, N gonorrhoeae is responsible for 53 - 80% of male urethritis cases, 20 -
40% of female prostitutes are infected with gonorrhoea along with 3 - 10% of 
pregnant females (Alary, 1997). In KZN, the prevalence of N gonorrhoeae was 
reported to be 52% amongst males (Sturm et al., 2004) and 12% amongst females 
(Moodley et al., 2002b ). 
2.4 Pathogenesis of Neisseria gonorrhoeae 
Gonorrhoea is a highly infectious disease and requires a low organism load to cause 
infection (Freeman, 1985). Spread of the disease is primarily through sexual contact. 
Table 2.2 summarises the surface elements of gonococcal cells that play an important 
role in the initial interaction with host cells and which often determine whether 
infection will occur (Heckels, 1978). 
The first step in the pathogenesis of N gonorrhoeae is the attachment of the organism 
to the mucosa! surface of non-ciliated epithelial cells which is mediated by pili 
(fimbriae) or by outer membrane proteins or both (Freeman, 1985). The main outer 
membrane components which are involved with adherence and invasion of the host 
cell are Opa, an opacity surface protein, Por, a major porin protein, Rmp, an outer 
membrane protein common to all strains of N gonorrhoeae and lipooligosaccharide 
(LOS) a structural component of the outer membrane (Todar, 2004). 
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The Opa protein is important in establishing infection, since it plays a major role in 
adherence to epithelial cells (Ram and Rice, 2001). Once the organism has attached to 
the surface of the host cell, it undergoes endocytosis and is eventually released by 
exocytosis. Por, which is found in the outer membrane of N gonorrhoeae is thought 
to mediate invasion of the host cell and promotes virulence in N gonorrhoeae. LOS is 
released during infection and stimulates the production of tumor necrosis factor 
(TNF) which results in cell damage. Rmp blocks the bactericidal antibodies designed 
to eliminate LOS and Por. Transferrin and lactoferrin receptors scavenge transferrin­
and lactoferrin-bound iron from the host (Todar, 2004). 
Table 2.2 : Surface components of N gonorrhoeae that play a role in virulence 
(Todar, 2004) 
Component Location Role 
PilE Fimbrial protein 
Initial binding to epithelial 
cells 
Opa Outer membrane protein Contributes to invasion 
Por Outer membrane protein 
Prevents phagolysosome 
formation in neutrophils 
Responsible for the 
formation of ineffective 
Rmp Outer membrane protein antibodies that inhibit 
bactericidal activity against 
Por and LOS 
Responsible for 
LOS Outer membrane lipooligosaccharide inflammatory response and 
release of TNF 
Tbp 1 and Tbp2 
Outer membrane transferrin 
Iron acquisition 
receptors 
Lbp Outer membrane lactoferrin receptor Iron acquisition 
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2.5 Clinical Manifestations of Neisseria gonorrhoeae 
Gonorrhoea commonly infects the mucous membranes and results in a discharge of 
pus that is more obvious in males than in females. N gonorrhoeae may colonise and 
infect the urethra, pharynx, rectum and conjunctiva in males. Mucosa! surfaces in 
females that are most commonly infected are the endocervix, urethra, rectum, pharynx 
and conjunctiva (Todar, 2004). 
Asymptomatic infection with N gonorrhoeae is commoner in females than males 
(Morello and Bohnhoff, 1980). Symptoms usually develop within 10 days of 
infection. The most common symptoms in females are increased vaginal discharge 
and dysuria (Ram and Rice, 2001) while urethral discharge, dysuria (Oates and 
Csonka, 1990), as well as swelling and pain in the urethral tissue are common in 
males (Todar, 2004). 
Infection in women may spread from the endocervix to the uterus, fallopian tubes and 
ovaries. This may result in complications such as pelvic inflammatory disease, ectopic 
pregnancies and infertility (Todar, 2004). In addition, the organism may spread into 
the peritoneal cavity and cause a peri-hepatitis syndrome (Fitz-Hugh-Curtis 
Syndrome) (PeaceHealth, 2006). Gonorrhoea in males is also characterised by 
infection of the urethral mucosa, resulting in urethritis as well as infection of the 
testicles and the prostrate (Todar, 2004). 
Often, gonorrhoea may be transmitted during birth. The most common manifestation 
in infants is a form of conjunctivitis called gonococcal ophthalmia neonatorum which 
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results in purulent discharge and if left untreated can lead to corneal scamng 
(Robertson et al., 1989) and eventually to blindness. 
2.6 Treatment of Neisseria gonorrhoeae 
WHO guidelines recommend third generation cephalosporins, fluoroquinolones or 
spectinomycin for the treatment for gonococcal infection. (Lawung et al., 2005). The 
United States Centers for Disease Control and Prevention currently recommends that 
uncomplicated infection with N gonorrhoeae be treated with third generation 
cephalosporins. Fluoroquinolones are not recommended. Spectinomycin may be 
considered as an alternative to the third generation cephalosporins (Barclay, 2007). 
According to Oates and Csonka (1990) and Zheng et al (2003) the purpose of 
treatment of infection with a pathogen is to eliminate the pathogen as quickly as 
possible from the body, thus limiting its transmission. However, many problems 
challenge the prompt treatment of gonorrhoea, including a lack of proper facilities to 
accurately diagnose and treat the infection especially in resource poor settings. This 
prompted WHO to adopt the syndromic approach for the management of sexually 
transmitted infections. 
A treatment regimen in which the organism is susceptible to the drug will result in 
elimination of the pathogen (Robertson et al., 1989). The antibiotics prescribed as part 
of the syndromic management package should therefore be based on the susceptibility 
pattern of the antimicrobial agent. This varies between different geographical areas 
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(Robertson et al., 1989; Arreaza et al., 2002; Salam et al., 2005). Therefore treatment 
regimens should be guided by regular susceptibility pattern surveillance. WHO 
guidelines suggest that once resistance to a particular agent reaches a prevalence of 
5%, it should no longer be used as empirical therapy (Tapsall, 2001). 
South Africa adopted the syndromic approach for the management of STis in 1995 
and is now widely practiced (Moodley et al., 2001 ). The syndromic management 
approach is based on algorithms which are formulated based on patients symptoms 
(Moodley et al., 2001) as well as the causative organisms causing the symptoms and 
signs (Moodley et al., 2006). Often individuals are infected with more than one STI 
causing organisms. Syndromic management allows treatment to be prescribed that can 
potentially eliminate the most prevalent microbial causes of infection presenting as a 
clinical syndrome. Furthermore it allows patients to begin treatment much sooner 
than if they had to wait for results from a laboratory test. 
The drug currently used as part of syndromic management for the treatment of 
potential infection with N gonorrhoeae in South Africa is ciprofloxacin. This 
recommendation from the National Department of Health has not changed despite 
widespread evidence that more than 5% of isolates of N gonorrhoeae are resistant 
(personal correspondence: Prof P Moodley and Prof David Lewis). In KwaZulu Natal, 
this recommendation has recently been changed and ceftriaxone is the drug of choice. 
Spectinomycin is an older drug that has traditionally been used as part of syndromic 
management for the management of N gonorrhoeae in pregnant women and in 
people who are allergic to P-lactam agents (Bala et al., 2005; Moodley et al., 2006). 
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With the increased resistance of Neisseria gonorrhoeae to ciprofloxacin, this drug has 
now became a potential candidate for use as a first line agent. 
2. 7 Antimicrobial Resistance of Neisseria gonorrhoeae
Treatment regimens have been developed for the treatment of infection with N 
gonorrheoae. These regimens, however, regularly need to be altered as a result of the 
development of resistance to antimicrobial agents by N gonorrhoeae and it is this 
resistance that makes it difficult to keep gonorrhoea under control. Resistance to 
antibiotics such as penicillin, tetracycline, spectinomycin, ciprofloxacin and 
ceftriaxone developed at varying intervals after these drugs were introduced as 
treatment agents against infection with N gonorrhoeae (Li et al., 2000). 
N gonorrhoeae began to develop resistance to antibiotics in the late 1950's and this 
trend has continued to develop and spread worldwide (Arreaza et al., 2003). For 
example, in investigations carried out in 1938, in the USA, it was found that the 
majority of N gonorrhoeae strains were susceptible to sulphonamides, which was the 
treatment agent at the time but 10 years later, by 1948, 80% of N gonorrhoeae 
isolates were resistant to the same drug making it an ineffective treatment modality 
for infection with N gonorrhoeae (Conte Jr. and Barriere, 1992). 
N gonorrhoeae is capable of adjusting to adverse conditions in order to survive, The 
increased use of certain antimicrobial agents has allowed this bacterium to develop 
resistance mechanisms against many antimicrobials, rendering them ineffective .. 
Although certain drugs such as penicillin, are no longer prescribed for the treatment of 
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gonorrhoea, they can still be used to treat other unrelated infections thus exerting 
selective pressure on N gonorrhoeae isolates (Lawung et al., 2005). Acquired 
resistance may also exist in N gonorrhoeae, where resistance genes are exchanged 
between organisms as well as organisms and the environment (Heritage, 2006). 
2. 7.1 Penicillin Resistant N. gonorrhoeae
It has been stated that the discovery of penicillin by Sir Alexander Fleming, around 
1928, transformed the treatment of infectious diseases. This /3 - lactam antibiotic 
works by binding to an enzyme that produces peptidoglycan which is an essential part 
of the cell wall. Cell wall synthesis is thus prevented. Penicillin, which occurs 
naturally is active against both Gram negative and Gram positive organisms. There 
are also semi-synthetic penicillins which are produced by modification of the side 
chain of the /3 - lactam ring structure, which are active against a number of pathogens 
(Wilson, 2000). 
For a number of years penicillin was used as a first line treatment agent against 
gonococcal infection (Wilson, 2000). According to Chenia et al (1997), penicillin has 
been used to treat gonorrhoea since 1943. However, in the mid 1970's, strains of N 
gonorrhoeae capable of producing penicillinase emerged (Oates and Csonka, 1990; 
Salam et al., 2005). This resulted in decreased efficacy of penicillin for the treatment 
of infection with N gonorrhoeae. The mode of action of the enzyme penicillinase is 
to break open the /3 -lactam ring structure, thereby destroying the antibiotic (Wilson, 
2000). Penicillinase-producing Neisseria gonorrhoeae (PPNG) was first isolated in 
1976 in the Far East and West Africa (Chenia et al., 1997; Cheng, 1989). 
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The TEM-1 type fJ -lactamase gene is carried on a plasmid (Tapsall, 2001) and codes 
for penicillinase, hence this type of resistance is plasmid mediated. It is thought that 
an R-plasmid carrying the fJ -lactamase gene was transferred to N gonorrhoeae from 
Enterobacteriaceae (Conte Jr. and Barriere, 1992). Since then the plasmids carrying 
resistance genes have spread rapidly worldwide, rendering N gonorrhoeae resistant to 
penicillin and in turn creating a major problem as far as treatment of gonorrhoea is 
concerned. 
The resistance genes are carried on plasmids of varying sizes. The isolates from the 
Far East that were among the first PPNG isolates discovered were found to carry a 4.4 
megadalton (MDa) plasmid named the "Asian" plasmid, which was associated with a 
24.5 MDa plasmid. Similarly, the initial PPNG strains isolated in West Africa 
contained a 3.2 MDa plasmid coding for /J -lactamase production named the 
"African" plasmid (Oates and Csonka, 1990; Cheng, 1989), which was discovered in 
1981 (Tapsall, 2001). Altogether, six plasmids have been described (table 2.3) and it 
is believed that PPNG strains may contain a 2.6 MDa cryptic plasmid, a 24.5 MDa 
conjugative plasmid and a 25.2 MDa TetM conjugative plasmid (Chenia et al., 1997). 
Table 2.3 : Various plasmids carried by PPNG strains, responsible for /J -lactamase 
production (Chenia et al., 1997) 
Name Size (MDa) 
African 3.2 
Asian 4.4 





As a result of its association with the large 24.5 MDa conjugative plasmid, the Asian 
plasmid is thought to disseminate more rapidly (Robertson et al., 1989). 
The first PPNG strains were isolated in Durban, South Africa in 1977 and have spread 
widely in the province and the country. Table 2.4 documents this increasing pattern. 
Currently, the breakpoint for penicillin sensitivity (PEN-S) is � 0.06 mg/L, 
intermediate strains are at 0.5 mg/L while chromosomally mediated resistance is � 2 
mg/L and plasmid mediated resistance is � 8 mg/L (NCCLS Guidelines, 1999; 
Moodley et al., 2001 ). 
Table 2.4: Increase in PPNG strains in Durban, South Africa (Chenia et al., 1997; 
Moodley et al., 2001) 






These statistics are relatively low when compared to countries like the Phillipines and 
Vietnam which had PPNG prevalence rates of 79% and 62. 7% respectively by 1998 
(Tapsall, 2001). 
Plasmid mediated resistance is not the only type of resistance present in N 
gonorrhoeae. Resistance to penicillin can also be chromosomally mediated and 
strains displaying this type of resistance are termed CMRNG (chromosomally 
mediated resistant Neisseria gonorrrhoeae). This type of resistance developed in a 
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stepwise manner, over many years as increases in penicillin doses to treat gonorrhoea 
resulted in treatment failures. Chromosomally mediated resistance is mainly as a 
result of mutations at various loci, namely penA, penB and mtr (Cheng, 1989). 
According to Swanson and Meyer (1984), penicillin binding proteins (PBP's) are 
equivalent to penicillin sensitive enzymes and these are present in the cell envelope 
and play a role in cell wall metabolism in Gram negative organisms. The penA locus 
in N gonorrhoeae codes for PBPl and PBP2. Any mutations in either one of these 
PBP's results in their affinity for penicillin declining, thereby decreasing the 
susceptibility if the organism to the drug, resulting in resistance. Mutations to the 
penB locus cause a decline in the permeability of the cell wall to certain antibiotics 
while mutations to the mtr locus result in resistance to a number of antibiotics. 
Collectively these mutations result in penicillin resistance (Tapsall, 2001). 
Neisseria gonorrhoeae has 4 PBP's, PBPl, 2, 3 and 4 (Ropp et al., 2001). PBP's 1 
and 2 are usually the target of penicillin activity as they have a high affinity for the 
drug especially PBP2. PBPl is likely to be partially responsible for high level 
penicillin resistance and is known to cause a 1000-fold increase in penicillin MI Cs in 
combination with decreased cell wall permeability. The ponA gene codes for PBPl 
(Ropp and Nicholas, 1997). 
An investigation by Ropp et al (2001) concluded that chromosomally mediated 
resistance to penicillin in N gonorrhoeae occurs as the result of the stepwise 
acquisition of resistance genes by susceptible N gonorrhoeae organisms, causing an 
increase in penicillin resistance until treatment failure occurs. One such step is the 
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acquisition of an altered ponA gene which in turn encodes an altered PBPl with a 3 to 
4 fold lower penicillin acylation rate in comparison with the wildtype (Ropp et al., 
2001). 
Since a decrease in acylation is insufficient to convert an intermediate resistant strain 
to a high level resistant strain the penC locus was also thought to play a role. Not 
much is known about this spontaneous mutation which occurs on an unidentified 
locus, except that it aids the ponA mutation in the mediation of high level penicillin 
resistance in N. gonorrhoeae (Ropp et al., 2001). 
It is possible for both plasmid and chromosomally mediated resistance to co-exist in a 
single isolate (Tapsall, 2001 ). Since the prevalence of penicillin resistance is so high, 
other antimicrobial agents have had to substitute penicillin as a treatment for 
gonorrhoea. Spectinomycin is most commonly used against PPNG strains together 
with the new generation cephalosporins (Salam et al., 2005) while spectinomycin and 
ceftriaxone are used to counteract CMRNG strains (Robertson et al., 1989). 
2. 7.2 Tetracycline Resistant N. gonorrhoeae
Tetracycline is a broad spectrum antibiotic that inhibits protein synthesis at the level 
of the 30S ribosomal subunit (Quesnel and Russell, 1983). This antibiotic binds 
reversibly to the ribosome and prevents the binding of tRNA to the acceptor site 
resulting in a bacteriostatic effect, in both Gram positive and Gram negative 
organisms (Wilson, 2000). 
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The gonococcus is however, resistant to tetracycline in many parts of the world hence 
the inability of the drug to be used as a first line treatment agent. Resistance to 
tetracycline can either be plasmid or chromosomally mediated. Plasmid mediated 
resistance is however more common and responsible for high level resistance (Conte 
Jr. and Barriere, 1992; Quesnel and Russell, 1983). High level resistance to 
tetracycline first emerged in the USA in 1983 followed by emergence in the 
Netherlands in 1985 (Chalkley et al., 1997). 
Plasmid mediated resistance occurs as a result of the presence of the TetM gene on a 
conjugative plasmid in N gonorrheoae (Todar, 2004; Moodley et al., 2006) while low 
level chromosomally mediated resistance is due to mutations in the mfr and penB 
genes (Tapsall, 2001 ). As previously described for penicillin, alterations in the mfr
gene results in resistance to a number of antibiotics while alterations in the penB locus 
alters the permeability of the cell wall to certain drugs including tetracycline and 
penicillin (Tapsall, 2001). When these mutations occur in combination with 
mutations in the tet gene, the MIC is said to increase 16 fold. The presence of the tet
gene mutation or the mfr mutation alone will result in a 4 fold increase and a 2 fold 
increase respectively while a combination of mutations in the tet and mfr genes or mfr
and penB genes result in 4 fold increases in MICs when compared to the wildtype 
(Johnson and Morse, 1988). 
Recently, another tetracycline resistance factor has been characterised by Hu et al 
(2005). The rpsJ resistance determinant has been described as the first gene that is 
specific for chromosomally mediated tetracycline resistance. This gene codes for the 
S 10 ribosomal protein in N gonorrhoeae and a G ➔ A point mutation in this gene 
causes a val ➔ met alteration (Hu et al., 2005). 
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This mutation occurs at the binding site of tetracycline and decreases the affinity of 
the organism for the drug. The rpsJ gene mutation is the only tetracycline resistance 
determinant in N gonorrhoeae to work independently of any other resistance 
determinant and can cause a 3 to 4 fold increase in tetracycline MICs whereas certain 
resistance factors require a synergistic relationship with other resistance factors to 
increase tetracycline MICs (e.g. penB and mfr only increase tetracycline MICs when 
they occur in combination in a single organism). A combination of mtr, penB and rspJ 
resistance determinants will result in high level tetracycline resistance (Hu et al., 
2005). 
The breakpoints for tetracycline resistance are : tetracycline susceptible (TET-S) 
� 0.25 mg/L, plasmid mediated tetracycline resistant N gonorrhoeae (TRNG) � 16 
mg/L and chromosomally mediated tetracycline resistant N. gonorrhoeae (CMRNG) 
at between 1 - 8 mg/L (NCCLS Guidelines, 1999; Moodley et al., 2001). 
According to Moodley et al (2001 ), Zaire was the first African country to declare 
tetracycline resistant N gonorrhoeae strains. High level resistance emerged in South 
Africa in 1994 from Bloemfontein and TRN G appeared in KwaZulu Natal in 1998. 
High level tetracycline resistance in N gonorrhoeae is mediated by via the plasmid 
borne TetM gene (Tapsall, 2001). The gene is carried on a 25.2 MDa conjugative 
plasmid and is responsible for inhibiting protein synthesis, leading to tetracycline 
resistance by coding for proteins that interact with the host ribosome (Johnson and 
Morse, 1988). The TetM determinant is said to be of Streptococcal origin (Todar, 
2004). Two types of TetM gene are known to exist, namely the American and Dutch 
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types and according to Chalkley et al (l 997), the Dutch type plasmid is 40.5 kb in size 
while the American type is 42.8 kb in size. The first TRNG isolates from Botswana 
were found to carry the American type plasmid which may have been transferred 
from Botswana or Namibia to South Africa. 
Tetracycline can no longer be used effectively as a treatment against gonorrhoea as a 
result of the high levels of resistance that have developed (Tapsall, 2001 ), due mainly 
to the overuse of tetracycline as well as the ease with which resistance genes are 
transferred across borders. In KZN alone, within 18 to 24 months the prevalence of 
TRNG strains increased from 3% to more than 50% (Moodley et al., 2001). TRNG 
prevalence rates are also high in countries like Singapore and the Solomon Islands, 
which showed rates of 84% and 74% of TRNG strains respectively by 1998 (Tapsall, 
200 I). 
2.7.3 Quinolone Resistant N. gonorrltoeae 
The quinolones are a group of antibiotics that inhibit protein synthesis (Johnson and 
Morse, 1988) by targeting the topoisomerases including DNA gyrase (Tapsall, 2001), 
which is responsible for the supercoiling of DNA. They have a bactericidal effect. 
Quinolones are usually derived from nalidixic acid and the addition of a fluorine 
molecule onto the structure has resulted in a new group of antibiotics called 
fluoroquinolones (Wilson, 2000). 
As resistance of N gonorrhoeae to penicillin, tetracycline, spectinomycin and other 
antimicrobial agents became more prevalent, fluoroquinolones were regarded as the 
most effective treatment against gonococcal infection. Resistance to these drugs is 
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becoming common (Knapp et al., 1997) and this resistance seems to be exclusively 
chromosomally mediated (Johnson and Morse, 1988). 
Tapsall (2001) describes resistance mechanisms that occur against quinolones in N 
gonorrhoeae. These include : (i) the inability of the drug to reach its target site and 
(ii) the alteration of the DNA gyrase due to mutations in the gyrA gene, topoisomerase
IV or the pare gene (Tapsall, 2001). 
The mutations that occur in the gyrA and pare genes, which code for DNA gyrase 
subunit A and topoisomerase IV, respectively, result in multiple amino acid changes 
(Knapp et al., 1997) resulting in an inability of the drug to bind to the target site. In 
addition mutations in pare seem to occur in the presence of mutations in gyrA. The 
mechanism of low level resistance is not well known (Tapsall, 2001). 
Isolates of N. gonorrhoeae are considered resistant to ciprofloxacin at an MIC of� 1 
mg/L, susceptible at an MIC of� 0.06 mg/L and intermediate at an MIC of 0.12 - 0.5 
mg/L (NCCLS Guidelines, 1999). 
Fluoroquinolone resistance is fast becoming a global phenomenon, occurring most 
frequently in the Far East, Philippines, Hong Kong and Japan (Knapp, 1997). The 
prevalence of fluoroquinolone resistance in Hong Kong increased from 7. 7% in 1995 
to 24% in 1996, while the prevalence in Japan increased from 6.6% in 1993 to 24.2% 
in 1998 (Tanaka et al., 2000). Resistance to ciprofloxacin first appeared in 2000 in 
Spain and the prevalence of resistant strains rose dramatically from 2.3% in 2000 to 
9.9% in 2001 (Arreaza et al., 2003). 
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Quinolone resistance has also been on the increase in South Africa. In a study 
conducted by Moodley et al in Durban, KwaZulu Natal, it was recorded that 100% of 
N. gonorrhoeae isolates had MICs of �0.007 mg/L in 1995 but by 2000 only 71 % of
the isolates fell into this category. Furthermore, 4% of the isolates showed MICs of 
0.125 mg/L to ciprofloxacin in 1999. Similar trends were observed for ofloxacin. 
These trends could be attributed to the fact that the use of quinolones rose 
dramatically in Durban from 1996 to 1997 (Moodley et al., 2001 ). In another study 
conducted in Durban in 2006, 22% of isolates were resistant to ciprofl.oxacin at an 
MIC of 2".: 2 mg/L (Moodley et al., 2006). Emergence of resistance to ciprofloxacin 
implies that the efficacy of quinolones against N. gonorrheoae has decreased. 
2. 7.4 Cephalosporin Resistant N. gonorrhoeae
Cephalosporins are structurally and functionally very similar to the penicillins. This 
means that they work by inhibiting cell wall synthesis. Cephalosporins also contain a 
/3 -lactam ring and modification of the side chains of this /J - lactam ring results in 
the development of various drugs. It is in this way that the many different generations 
of cephalosporin drugs have been developed. The very first cephalosporin, 
cephalothin was developed in the 1960's and second generation cephalosporins were 
introduced in 1975 while the third generation cephalosporins were developed in the 
1980's (Wilson, 2000). Cefepime, a fourth generation cephalosporin was approved for 
use by the FDA in 1996 (Mascaretti, 2003). 
The third generation cephalosporins are currently recommended for the treatment of 
gonorrhoea. Ceftriaxone became a recommended first line agent against N. 
gonorrhoeae in 1989 in the USA. This was based on CDC recommendations after the 
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organism had developed resistance to penicillin, tetracycline and spectinomycin 
(Schwebke et al., 1995). A recent study by Ison et al (2004) concluded that 
ceftriaxone ( or cefixime) should be the treatment of choice, ahead of other 
cephalosporins, to replace ciprofloxacin against N. gonorrhoeae (Ison et al., 2004). 
According to Schwebke et al (1995) decreased susceptibility to ceftriaxone is defined 
as� 0.06 mg/L. Strains from various countries demonstrate decreased susceptibility to 
ceftriaxone and other cephalosporins while some countries display outright resistance 
(Schwebke et al., 1995). 
The mechanisms of resistance displayed by N. gonorrhoeae to cephalosporins are 
similar to those described for penicillin. Mutations at the penA, penB and mtr loci also 
cause resistance to cephalosporins (Tapsall, 2001 ). High level resistance of 
cephalosporins to N. gonorrhoeae has not been described. Resistance is therefore 
chromosomally mediated, by mutations which result in altered affinity to PBP's as 
well as decreased membrane permeability (Schwebke et al., 1995). /3 - lactamases 
capable of inactivating cephalosporins, called cephalosporinases, are found in some 
Gram negative organisms but not yet in N. gonorrhoeae (Tapsall, 2001) and third 
generation cephalosporins like ceftriaxone are not hydrolysed by the TEM-type /3 -
lactamase R plasmid in N. gonorrhoeae (Russo and Thompson, 1984). A certain 
degree of cross resistance occurs between cephalosporins and penicillin and according 
to Wilson (2000), about 10% of people who are hypersensitive to penicillins are also 
hypersensitive to cephalosporins. 
In the USA, ceftriaxone was introduced against N. gonorrhoeae in 1985 and by 1991, 
87.6% of gonorrhoea cases were treated with this drug. Despite this the MICs of 
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ceftriaxone began to decrease with more than 2.6% of isolates having an MIC that 
was;?: 0.06 mg/Lin 1991. Interestingly, the widespread use of ceftriaxone in the USA 
appeared not to promote resistance (Schwebke et al., 1995). 
In South Africa the use of ceftriaxone is also increasing (Moodley et al., 2001). A 
study done in Durban in 2001, indicated that no resistance to ceftriaxone was present 
but MI Cs did increase significantly with 100% of isolates having an MIC �0.007 
mg/Lin 1995 while this figure decreased to 53% in 2000. Furthermore, 5% of isolates 
were at an MIC of 0.06 mg/L. These increasing trends are present on a global scale 
(Moodley et al., 2006). 
2. 7.5 Macrolide Resistant N. gonorrlteoae
Erythromycin and azithromycin are the most common macrolides used against N.
gonorrhoea. These drugs work by binding to the 50S ribosomal subunit thereby 
inhibiting nucleic acid production and in turn preventing elongation of the peptide 
chain . Erythromycin, specifically , interferes with translocation (Russo and Thompson, 
1984) and has a bactericidal effect but only at high concentrations (Wilson, 2000). 
Macrolides are usually used if the patient is allergic to cephalosporins (Ng et al., 
2002). 
N. gonorrhoeae displays resistance to macrolides via efflux pumps, which mediate
low level resistance or via modification of enzymes or mutations at the target site that 
result in a decreased affinity for the drug (Ng et al., 2002). The mtrRCDE genes 
encode the mtrC-mtrD-mtrE efflux pump that is responsible for the export of 
azithromycin and erythromycin and is also one of the first efflux pumps described for 
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N gonorrhoeae. The mutations occur due to the 23S rRNA methylases erm(B), 
erm(C) and erm(F) which alter the antibiotic target site (Ng et al., 2002), by single 
base substitutions (Verster and Douthwaite, 2001). These methods of resistance are 
chromosomally mediated while plasmid mediated resistance is extremely rare (Russo 
and Thompson, 1984). Mutations that result in erythromycin resistance may also 
cause azithromycin resistance (Moodley et al., 2001). 
Erythromycin was first introduced in 1952 and became a first line treatment agent for 
pregnant women with gonorrhoea, who were allergic to the drug of choice, penicillin. 
This occurred in 1975 but by 1977 resistance was beginning to develop (Ehret et al., 
1995). 
The breakpoints for erythromycin in N gonorrhoeae are as follows : resistant � 2 
mg/L, intermediate 0.125 - 0.5 mg/L and susceptible �0.05 mg/L (NCCLS 
Guidelines, 1999). Azithromycin is a relatively new antibiotic, that was developed by 
introducing a nitrogen atom into the macrolide lactone ring (Ehret et al., 1995) and 
susceptibility data is not readily available on the drug but it has been reported that 
treatment failure occurs with doses as low as 1 g and high doses are not tolerated well, 
with numerous side effects (Tapsall, 2001). The high rates of treatment failure could 
be attributed to the fact that azithromycin is structurally very similar to erythromycin 
(Moodley et al., 2001). 
Azithromycin resistance was detected in Canada in 1997 with 95% of isolates in 
Quebec displaying resistance (Ng et al., 2002). Moodley et al (2001) reported an 
increase in MICs of N gonorrhoeae to azithromycin in Durban, South Africa. A 
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similar trend was reported for erythromycin with the MIC range falling between 0.007 
mg/L to 0.5 mg/L. By 2000 the MIC range had increased to 0.03 mg/L to 4 mg/L. The 
trend of the erythromycin MICs leaned toward resistance with 26% of isolates 
displaying an MIC of 0.5 mg/L in 2000 while this figure was 14% in 1997 (Moodley 
et al., 2001). 
2.7.6 Spectinomycin Resistant N. gonorrhoeae 
Spectinomycin is an aminocyclitol antibiotic which is related to the aminoglycoside 
antibiotics. It is closely related to streptomycin structurally and characteristically 
(Russo and Thompson, 1984). Spectinomycin does, however, possess qualities that 
distinguish it from true aminoglycosides. When compared to aminoglycosides, 
spectinomycin is known to display inferior bactericidal qualities, it also produces a 
bacteriostatic effect as opposed to the bactericidal effect achieved by the 
aminoglycosides (Conte Jr. and Barriere, 1992). Structural differences also exist 
between spectinomycin and the aminoglycosides, since spectinomycin lacks an amino 
sugar, present in aminoglycosides (Quesnel and Russell, 1983). According to Conte Jr 
and Bar iere (1992) and Russo and Thompson (1984) the purpose of spectinomycin is 
for the treatment of uncomplicated gonococcal infection in individuals who are either 
allergic to penicillin (and / or other agents used to treat gonorrhoea) or who are 
infected with resistant strains. 
The mode of action of spectinomycin is the inhibition of protein synthesis by binding 
to the 30S ribosomal subunit (Quesnel and Russell, 1983; Russo and Thompson, 
1984 ). This drug does not however cause mis-reading of codons, hence its 
bacteriostatic effect (Quesnel and Russell, 1983 ). 
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The development of drug resistance and treatment failure with sulphonamides and 
penicillin led to new antimicrobial regimens being recommended for treatment of 
gonorrhoea. Spectinomycin was was recommended as a first line agent against N.
gonorrhoeae, in the USA (Boslego et al., 1986). It has also been recommended in 
patients who are allergic to cephalosporins. In some countries, where the prevalence 
of quinolone resistance is high, spectinomycin has also been recommended 
(Workowski et al., 2002). In South Africa and other countries, spectinomycin is used 
as an alternative to ciprofloxacin during pregnancy due to the potential teratogenic 
effects of ciprofloxacin (Moodley et al., 2006). 
The inclusion of spectinomycin in treatment regimens against gonorrhoea is becoming 
more common worldwide although there is not much clinical evidence available to 
support the use of the drug against N. gonorrhoeae. MICs of this agent to N 
gonorrhoeae has shown a trend to right. According to a World Health Organisation 
(WHO) report in 2001, penicillin and the quinolones have the highest resistance 
trends in N. gonorrhoeae followed closely by tetracycline. 
A study carried out in Brazil showed that 46. 7% of PPNG isolates were resistant to 
tetracycline while 100% of isolates were susceptible to spectinomycin (Belda Jr. et 
al., 2002). Isolates from Korea, Bangladesh, USA, Finland and Dubai, tested during 
1993 to 1998 demonstrated susceptibility to spectinomycin (Tapsall, 2001 ). In 1997, 
33.4% of N. gonorrhoeae isolates in the USA were resistant to penicillin, tetracycline 
or both (WHO, 2001). In Bangladesh in 1999, 49% of isolates were resistant to 
ciprofloxacin (Rahman et al., 2002). With gonococcal isolates showing such high 
levels of resistance to first line agents like penicillin, tetracycline and ciprofloxacin, 
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an alternative is needed. Spectinomycin would seem like the best option, considering 
that most isolates are susceptible. 
The situation is identical on the African continent and in South Africa, where a large 
proportion of N. gonorrhoeae isolates demonstrate resistance to drugs recommended 
for syndromic management (Moodley et al., 2001). Spectinomycin may prove to be 
an effective alternative. 
Spectinomycin resistance can either be plasmid or chromosomally mediated. The 
aadA gene which is found on an R-plasmid codes for an adenyltransferase enzyme 
that results in spectinomycin resistance via drug inactivation. This gene is present in 
E. coli and many Gram negative bacteria but has not yet been transferred into N.
gonorrhoeae (Russo and Thompson, 1984). There is, however, speculation that the 
genes coding for the antibiotic inactivating enzyme will one day be acquired by the 
gonococcus (Tapsall, 2001 ). Thus far, all spectinomycin resistance in N. gonorrhoeae 
has been chromosomally mediated via a single step mutation which results in high 
level resistance (Tapsall, 2001 ). The 30S ribosomal subunit is altered so that 
spectinomycin cannot bind to it and this results from mutations in the spc locus. The 
spc locus is also linked to the str and rif loci which mediate streptomycin resistance 
and rifampicin resistance, respectively (Johnson and Morse, 1988). Very little is 
known about the exact mechanism of resistance. 
According to NCCLS guidelines, the breakpoints for spectinomycin are: susceptible 
� 32 mg/L, intermediate = 64 mg/L and resistant � 128 mg/L. In a study conducted 
by Moodley et al in Durban, KZN (2001) it was discovered that the MICs of 
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spectinomycin increased dramatically over a 3 year period. In 1997, 28% of N 
gonorrhoeae isolates had MICs � 16 mg/L, during 1998/1999 this increased to 52% 
of isolates while by 1999/2000, this figure was 100%. This clearly indicated the 
distinct movement toward decreased susceptibility (Moodley et al., 2001). 
A study conducted in Durban at the beginning of 2006 further supported this trend 
with 89% of isolates having an MIC of 16 mg/L and 3% of isolates having an MIC of 
32 mg/L. Other antimicrobial agents tested against N gonorrhoeae in this study 
included penicillin, tetracycline, ciprofloxacin and ceftriaxone. Twenty one percent of 
the isolates were resistant to penicillin some, at levels as high as 128 mg/L, of equal 
importance though, was the fact that only 2% of the isolates were susceptible to the 
drug. Seventy eight percent of the isolates showed tetracycline resistance with MI Cs 
also reaching levels of 128 mg/L while 43% of the isolates were resistant to 
ciprofloxacin and 99% showed a decreased susceptibility to ceftriaxone (personal 
correspondence). Spectinomycin therefore seems to be the most promising in terms of 
susceptibility as none of the MICs of the isolates have passed the resistance 
breakpoint. 
During its use as a second line treatment agent for gonorrhoea (i.e. before the 
emergence of PPNG), spectinomycin resistance was rare. However, it is now 
becoming a common occurrence worldwide. In 2004, Bala et al, reported on the first 
N gonorrhoeae isolate to show spectinomycin resistance in India. The MIC of the 
isolate was 128 mg/L and it was susceptible to penicillin, tetracycline, ciprofloxacin 
and ceftriaxone. At the same time, 11 % of N gonorrhoeae isolates in China were 
resistant to spectinomycin (Bala et al., 2004). 
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2. 7.6.1 Protein Synthesis and Spectinomycin
Spectinomycin is classified as an inhibitor of protein synthesis and works by binding 
to the 30S ribosomal subunit, halting its function (Quesnel and Russell, 1983). The 
first step in the process of protein synthesis is the formation of the initiation complex. 
Within this complex, the peptidyl donor site (P-site) on the large ribosomal subunit is 
occupied by the methionyl-transfer-RNA. The acceptor site is occupied by the 
aminoacyl tRNA appropriate to the next codon to be read. Peptidyl transferase is an 
enzyme which is responsible for attaching a methionine to the new amino acid via a 
peptide bond. During the next step, the partially formed peptide is translocated from 
the A-site to the P-site when the mRNA and the ribosome move, relative to one 
another. Simultaneously, the next mRNA codon moves into place, aligned with the A­
site for the next aminoacyl tRNA. This process continues and a peptide chain is 
formed by the amino acids, following the order of the mRNA. Eventually the process 
is terminated when a "nonsense" codon is processed (Conte Jr. and Barriere, 1992). 
Protein synthesis takes place in and around the ribosome. Ribosomes consist of 2 
subunits and in bacteria like N. gonorrhoeae, the 2 subunits are the 30S subunit (small 
subunit) and the 50S subunit (large subunit) which combine to form the 70S subunit 
(Gale et al., 1981). 
Protein synthesis is inhibited by spectinomycin as a result of the drug affecting the 
interaction between the ribosome and elongation factor-G (EF-G) (Johanson and 
Hughes, 1995). Spectinomycin interferes with translation of the peptide from the A­
site to the P-site by stabilizing helix 34, freezing the 30S subunit into an inactive 
conformation (Brink et al., 1994). 
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Spectinomycin resistance has been found to be involved with the 30S ribosomal 
subunit. Mutations occurring in this subunit result in organisms like N. gonorrhoeae 
being resistant to spectinomycin. The mutation is a transversion that occurs in the 16S 
rRNA genes of the 30S ribosomal subunit at the binding site for spectinomycin, G1064 
and Cll92 • This base pair occurs in the upper stem of helix 34 (Brink et al., 1994). 
According to Johanson and Hughes (1995), the C1192 transition was the first mutation 
identified in the l 6S rRNA resulting in spectinomycin resistance, the G1064 mutation 
was discovered later. It was also determined by these authors that any change of the 
G1064-C1192 base pair will result in spectinomycin resistance. There was also 
speculation that mutations at other points of helix 34 may disrupt its conformation, 
preventing the formation of the G1o64-C1192 base pair, thereby not allowing 
spectinomycin to bind (Johanson and Hughes, 1995). 
Although spectinomycin is widely used to treat gonorrhoea and there is a significant 
amount of resistance that has developed, there is very limited information available on 
resistance mechanisms for this drug. 
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Chapter 3 
Materials and Methods 
3.1 Bacterial Isolates 
Fifty three stored isolates of N gonorrhoeae were used in the experiments for this 
study. These isolates were selected based on their spectinomycin MICs so as to 
represent the spectrum from susceptible to decreased susceptibility. Of these, 28 
isolates were collected in 2000 and 25 isolates were collected in 2004. All isolates 
were from male patients attending the Prince Cyril Zulu STD Clinic in Durban. The 
stored samples were inoculated onto New York City (NYC) agar plates. These plates 
were incubated in 5% CO2 at 3 7
°C for 24 to 48 hours. 
DNA that was isolated from N gonorrhoeae cultures grown on NYC agar plates was 
used in Polymerase Chain Reaction (PCR). The isolates were also inoculated into 
Mueller-Hinton II broth and used for Minimum Inhibitory Concentration (MIC) tests 
which were done via the agar dilution method. 
3.2 Minimum Inhibitorv Concentration {MIC) 
The MIC of the N gonorrhoeae isolates for spectinomycin was determined using the 
agar dilution method, according to NCCLS guidelines (NCCLS Guidelines, 1999). 
Table 3:1 shows the MI Cs of these isolates for spectinomycin and other antibiotics. 
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Table 3.1 : MI Cs of isolates used in this study 
MIC {mg/L) 
Sample Spectinomycin Penicillin Tetracycline Ciprofloxacin Ceftriaxone 
Bl 32 1.0 128.0 8.0 0.031 
B2 64 0.25 64.0 S 0.007 0.062 
A9 32 0.5 2.0 S 0.007 0.031 
B24 64 1.0 128.0 8.0 S 0.007 
A25 64 0.25 64.0 S 0.007 S 0.007 
A35 64 0.5 64.0 S 0.007 S 0.007 
A42 64 0.125 1.0 S 0.007 S 0.007 
B43 32 2.0 128.0 S 0.007 S 0.007 
B58 64 2.0 2.0 S 0.007 0.031 
A72 64 0.5 64.0 4.0 S 0.007 
A80 32 0.25 64.0 4.0 S 0.007 
A94 64 0.125 0.5 S 0.007 S 0.007 
A102 64 0.5 32.0 S 0.007 S 0.007 
A108 32 0.062 16.0 S 0.007 S 0.007 
A120 64 0.25 64.0 8.0 S 0.007 
B137 32 0.015 16.0 S 0.007 S 0.007 
B153 64 1.0 64.0 S 0.007 S 0.007 
A155 64 0.125 1.0 S 0.007 S 0.007 
A164 32 0.25 128 8.0 S 0.007 
A170 64 0.125 32.0 2.0 S 0.007 
B186 32 0.125 1.0 S 0.007 S 0.007 
B200 64 <128.0 2.0 S 0.007 S 0.007 
Tl 124 32 Not Tested S 0.007 S 0.007 
Tl 189 16 Not Tested S 0.007 S 0.007 
Tl 192 32 Not Tested S 0.007 S 0.007 
127 065 32 Not Tested S 0.007 0.015 
127 072 64 Not Tested S 0.007 S 0.007 
127 222 16 Not Tested S 0.007 S 0.007 
USB 210 32 0.015 0.5 S 0.007 S 0.007 
USB 213 16 0.5 128.0 S 0.007 S 0.007 
USB 225 16 2.0 2.0 S 0.007 S 0.007 
USB 235 32 0.125 0.5 S 0.007 S 0.007 
USB 266 8 0.015 1.0 S 0.007 S 0.007 
USB 312 32 2.0 128.0 S 0.007 S 0.007 
USB 330 16 0.125 64.0 S 0.007 S 0.007 
USB 393 16 0.062 0.5 S 0.007 S 0.007 
USB 396 16 16.0 128.0 S 0.007 S 0.007 
USB 397 16 16.0 64.0 S 0.007 S 0.007 
USB 399 16 1.0 <128.0 S 0.007 S 0.007 
USB 462 8 0.125 0.75 S 0.007 S 0.007 
USB 491 16 32.0 64.0 S 0.007 S 0.007 
USB 517 8 32.0 0.5 S 0.007 S 0.007 
USB 553 4 0.25 0.25 S 0.007 S 0.007 
USB 557 8 2.0 0.5 S 0.007 S 0.007 
USB 563 8 1.0 64.0 S 0.007 S 0.007 
USB 569 8 1.0 16.0 S 0.007 S 0.007 
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USB 594 8 0.062 16.0 S 0.007 S 0.007 
USB 598 16 0.031 0.5 S 0.007 S 0.007 
USB 599 64 2.0 64.0 0.015 0.015 
USB 600 8 16.0 32.0 S 0.007 S 0.007 
USB 646 8 0.0625 16.0 S 0.007 S 0.007 
USB 648 8 0.25 0.5 S 0.007 S 0.007 
USB 970 16 128.0 64.0 S 0.007 S 0.007 
3.2.1 Stock Solution of Spectinomycin : 
A 256 mg/L stock solution of spectinomycin was made by dissolving the 
spectinomycin powder in distilled water (dH20). The total volume of the stock 
solution was 10 ml. The solution was aliquoted into cryovials in 1 ml amounts and 
frozen at -40°C until use. 
3.2.2 NYC Agar Plates for MIC Tests : 
For the purpose of the MIC tests, the antibiotic was incorporated into NYC agar 
plates. Twofold serial dilutions of the antibiotic were made by adding 1 ml of the 
spectinomycin stock solution to 9 ml of distilled water and mixing well, 5 ml of the 
solution was then serially diluted out, fifteen times to give a concentration range of 
128 mg/L to 0.007 mg/L. This was done in duplicate. 
The final volume of each NYC agar plate was 25 ml. Seventy two grams of GC agar 
base (Oxoid) was dissolved in 1440 ml of distilled water and autoclaved at 120
°
C for 
15 minutes. For the supplement, 1 % Isovitalex was used. 5% saponin and 60 ml of 
yeast autolysate were added to 100 ml of horse blood, this was subsequently left at 
room temperature for 15 minutes in order for the yeast autolysate to lyse the horse 
blood, after which it was added to the autoclaved medium and mixed well. 
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Twenty millilitres of the NYC medium was mixed with 5 ml of spectinomycin from 
the dilution series and aliquoted into petri dishes giving a final volume of 25 ml per 
agar plate. The agar plates were left to solidify at room temperature and stored in the 
refrigerator until use. One plate from each batch was incubated at 3 7°C for 24 hours in 
order to ensure sterility of the agar plates. If after 24 hours of incubation, no 
contamination was observed on the agar plates then they were used for the MIC tests. 
These agar plates were made in duplicate. 
3.2.3 Inoculation of NYC Agar Plates For MIC Tests : 
3.2.3.1 Preparation of Broth For MIC Inoculum : 
N gonorrhoeae was cultured in GC broth medium for the purpose of inoculating the 
NYC agar plates for the MIC tests. Eleven grams of Mueller-Hinton II broth powder 
was dissolved in 500 ml of distilled water and autoclaved at 120°C for 15 minutes. 
The broth was allowed to cool and was dispensed into sterile tubes in 1 ml amounts. 
3.2.3.2 Inoculation of Broth For MIC Inoculum : 
A sterile inoculating loop was used to pick up a single colony of N gonorrhoeae from 
24 hour NYC agar plate cultures and inoculated into the Mueller-Hinton II broth for 
each sample and vortexed. The turbidity was adjusted to a 0.5 McFarland standard 
and a 1 in 10 dilution of each sample was made. The control strain, Staphylococcus 
aureus A TCC 25923 was subjected to the same procedure. 
3.2.3.3 Inoculation of NYC Agar Plates for MIC Tests : 
A multipoint inoculator was used to inoculate the NYC agar plates containing 
spectinomycin. The wells and the pins of the multipoint inoculator were autoclaved at 
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120°C for 15 minutes. The NYC agar plates were removed from the refrigerator and 
allowed to dry in an incubator at 37°C until no moisture was visible on the lids of the 
plates. The first well of the inoculator was filled with 450 µl of Nigrosin ink which 
was used as a marker while the rest of the wells were filled with 450 µl of the 
inoculum and the last well contained 450 µl of the control. 
The pins of the multipoint inoculator were then dipped into the wells and 
subsequently touched onto the surface of each NYC agar plate containing 
spectinomycin. Each pin of the multipoint inoculator picks up 10 µl of sample and 
inoculates a spot onto the surface of the agar plates at a standardised concentration of 
10
4 
cfu/spot. Each agar plate containing spectinomycin was inoculated in this manner 
from the lowest concentration (i.e. 0.007 mg/L) to the highest concentration (i.e. 128 
mg/L) in order to prevent carry over of antibiotic from plate to plate. One plate 
containing no antibiotic was also inoculated as a "growth" control plate, this plate was 
inoculated first. 
These plates were incubated at 37°C, in 5% CO2 for 24 hours. The plates were read 
after 24 hours, failure of a sample to grow at a particular concentration of 
spectinomycin, indicated the MIC for that sample. 
According to NCCLS guidelines, the breakpoints for spectinomycin are defined as 
susceptible at ::;32 mg/L, intermediate at 64 mg/L and resistant at � 128 mg/L. 
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3.3 Total DNA Isolation 
The boiling method was used to isolate DNA from colonies of N gonorrhoeae, taken 
off 24 - 48 hour NYC agar plate cultures that had been incubated at 3 7°C in 5% CO2.
This procedure was carried out in 1.5 ml Eppendorff tubes. A sterile inoculating loop 
was used to scrape a loopful of culture from the NYC agar plates and added to 250 µl 
of sterile distilled water in the Eppendorff tubes. The tubes were centrifuged until the 
culture had been homogenised. This suspension was then boiled for 15 minutes in a 
waterbath, which was preheated to 100°C. Once cooled, the tubes were centrifuged 
for 15 minutes at 12 000 rpm. 
The cell debris formed a pellet at the bottom of the tube. The supematent containing 
the gonococcal DNA was aliquoted into clean 1.5 ml Eppendorff tubes and used in 
PCR reactions. 
3.4 Polymerase Chain Reaction (PCR) 
3.4.1 PCR for Detection of aadA Gene 
PCR was performed on N gonorrhoeae isolates so that the presence or absence of the 
aad.A gene could be confirmed. This gene is meant to confer spectinomycin resistance 
in N gonorrhoeae. The entire PCR procedure was done according to Clark et al 
(1999). The PCR reaction mixture had to be optimised in order to provide the best 
results. PCR for the detection of the aad.A gene was only performed on the isolates 
from 2004 since these had higher MICs. 
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3.4.1.1 Optimisation of PCR for the Detection of the aadA Gene : 
The dNTP and MgCh concentrations were varied. The volumes of the PCR buffer, 
the primers and the Taq polymerase all stayed constant, while that of the distilled 
water was varied in order to keep the final volume of the PCR reaction mixture at 40 
µl. The optimal PCR reaction mixture contained the components listed in Table 3 .2. 
3.4.1.2 PCR Reaction Mixture : 
The total DNA obtained from the isolation was used as a template in polymerase 
chain reaction (PCR) amplification. Forty microlitres of a PCR mastermix was 
prepared, containing 10 mM Tris-2.0 mM MgCh-50 mM KCl (pH 8.3), 100 µM 
deoxynucleotide triphosphates (dNTPs), 0.5 µM primer and 2.5U taq DNA 
polymerase. Ten microlitres of the gonococcal DNA was added to the PCR 
mastermix, to bring the total volume of the reaction mixture to 50 µl. 
3.4.1.3 PCR Cycling Conditions : 
The PCR reaction mixture was amplified in a thermocycler (Gene Amp PCR system 
9700). The cycling conditions were as follows : an initial denaturation for 10 minutes 
at 95°C, 30 cycles consisting of a 30 second denaturation step at 94°C, a 30 second 
annealing at 60°C and a 30 second extension step at 72
°
C, a 10 minute extension step 
at 72°C and incubation at 4°C until use. 
3.4.1.4 PCR Primers and Controls : 
The PCR positive control was an E. coli strain (C600, pHP 45Q) which is known to 
contain the aadA gene (this strain was kindly provided by Nancye C. Clark from the 
Centres for Disease Control and Prevention in Atlanta, USA). In the negative control 
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tube, IO µI of gonococcal DNA was replaced with IO µl of distilled water. 
The primers that were used to detect the aad.A gene were as follows 
5'-TGA TIT OCT GOT TAC GOT GAC-3' 
5'-CGC TAT GIT CIC TTG CIT TTG-3' (Clark et al., 1999) 
3.4.1.5 Electrophoresis of PCR Products : 
Detection of the aadA gene was done via electrophoresis. Following PCR 
amplification, IO µl aliquots of the amplified product were mixed with 3 µl of gel 
loading buffer and subsequently loaded into a 2% agarose gel submerged in a solution 
of 0.5X TBE buffer. A I 00 bp ladder was used as a marker. The 2% agarose gel also 
contained ethidium bromide for visualisation of the DNA bands. The DNA was 
visualised by UV fluorescence in the Gene Genius Bioimaging System. A 284 bp 
product was expected. 
Table 3.2: Optimal volumes for aad.A gene PCR reactions 
Component Volume (µl) 
Distilled Water (dH2O) 32 
PCR Buffer 5 
DNTP 0.5 
Forward Primer 
Reverse Primer I 
Taq Polymerase 0.5 
Total 40 
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3.4.2 PCR for Detection of 16S rRNA 
The N gonorrhoeae isolates were subjected to further PCR amplification of the 16S 
rRNA region, which is known to carry a mutation that is responsible for 
spectinomycin resistance in N gonorrhoeae, as well as other organisms, in various 
parts of the world. The PCR experiments were performed according to Galimand et al 
(2000). Optimisation of the PCR reaction mixture was done. Once amplified, the 
products were sequenced in order to determine the presence or absence of the 
mutation. 
3.4.2.1 Optimisation of PCR for the Detection of the 16S rRNA : 
The dNTP and MgCli concentrations and volumes utilised in the PCR reaction 
mixture were varied. PCR buffer, primers and Taq polymerase volumes and 
concentrations remained the same. The final volume of the PCR reaction mixture was 
90 µI. Optimal PCR conditions are listed in table 3 .3. 
3.4.2.2 PCR Reaction Mixture : 
The PCR reaction mixture was prepared containing l OX PCR buffer, 250 µM 
deoxynucleotide triphosphates (dNTPs), 20 pmol of each primer, 2.5U taq DNA 
polymerase and water. 10 µl of total N gonorrhoeae DNA (obtained by the boiling 
method) was used as a template and brought the total PCR reaction volume to 100 µI. 
3.4.2.3 PCR Cycling Conditions : 
Amplification was carried out in a thermocycler (Gene Amp PCR system 9700) under 
the following conditions : 2 minutes at 94°C, 30 cycles with 1 cycle consisting of 1 
minute at 94°C, 45 seconds at 56°C and 1 minute at 72°C, finally 7 minutes at 72°C 
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and incubation at 4°C until use. 
3.4.2.4 PCR Primers and Controls : 
No positive control was used in this PCR as an organism containing this particular 
mutation was not easily accessible. Furthermore, the size of the product expected was 
known and the products obtained were sequenced thereby giving the exact sequence 
of the mutation, if it was present, this negated the need for a positive control to be 
included in the procedure. The primers and the experimental procedure were obtained 
from an article by Galimand et al (2000). The primers were designed to detect the 16S 
rRNA region in the N gonorrhoeae genome that carry mutations G 1064 and C 1192 and 
gave a 373 bp product (Galimand et al., 2000). 10 µl of distilled water was used to 
substitute gonococcal DNA as a negative control. 
The primers used to detect the 16S rRNA were: 
F980: 5'-CTT ACC TGG TCT TGA CA-3' 
R1353: 5'- CGA TTA CTA GCG ATT CC-3' (Galimand et al., 2000) 
3.4.2.5 Electrophoresis of PCR Products : 
Electrophoresis of the amplified PCR products was carried out in 2% agarose gel. Ten 
microlitres of the amplified PCR product was mixed with 3 µl of gel loading buffer 
and loaded into an agarose gel submerged in 0.5X TBE buffer. A 100 bp DNA ladder 
was used as a marker. Ethidium bromide staining allowed for visualisation of the 
DNA bands under UV light in the Gene Genius Bioimaging System, after 
electrophoresis. A 3 73 bp product was expected. 
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Table 3.3 : Optimal volumes for 16S rRNA PCR reactions 
Component Volume (µI) 
Distilled Water (dH2O) 73.75 
PCR Buffer 10 
MgCh 2 
DNTP 1.25 
Primer F980 1 
Primer Rl 353 1 
Taq Polymerase 1 
Total 90 
3.4.3 Nested PCR For the Detection of 16S rRNA 
Even after optimisation, some of the bands appearing on the agarose gel subsequent to 
electrophoresis were still extremely faint. In light of this, a nested PCR had to be 
performed on the samples that were producing faint bands, in an attempt to intensify 
the DNA bands. The nested PCR method involves the amplification of DNA from the 
sample twice so as to increase the amount of DNA present, thereby increasing the 
intensity of the bands on the agarose gel. 
The reaction mixture for the first amplification was identical to that originally used to 
detect the 16S rRNA region of the N gonorrhoeae samples, after optimisation. 10 µl 
of template DNA was added to the 90 µl reaction mixture and amplified under the 
original conditions in a thermocycler (see section 3.4.2.3). Once the first round of 
amplification was complete, a second round was done by making a new reaction 
mixture with a total volume of 95 µl containing 1 OX PCR buffer, 10 mM 
deoxynucleotide triphosphates (dNTPs), 20 pmol of each primer, 2.5U taq DNA 
polymerase and water. The volumes of the components used in the reaction mixture 
are listed in table 3.4. 
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Table 3 .4 : Volumes of components used in nested PCR reaction mixture 
Component Volume (µI) 
Distilled Water (dH2O) 78.75 




Primer R1353 1 
Taq Polymerase 
Total 95 
Instead of 10 µl of template DNA being added to the reaction mixture, 5 µl of 
amplified PCR product (from the first round of amplification) was used as a template 
and added to the reaction mixture, to bring the total volume to 100 µl. This was then 
amplified again in a thermocycler, under identical conditions to the first round of 
amplification. This results in a larger amount of DNA being amplified, it is therefore 
expected to increase the intensity of the DNA bands fom1ed after electrophoresis and 
ethidium bromide staining. 
3.4.4 PCR for the Detection of the mtrR Gene 
The mtrR gene of the mtrRCDE efflux pump was amplified and subsequently 
sequenced to detect the presence or absence of mutations in this gene. 
3.4.4.1 PCR Reaction Mixture : 
The PCR reaction mixture contained 1 OX PCR buffer, 10 mM deoxynucleotide 
triphosphates (dNTPs), 5 pmol of each primer, 2.5U tag DNA polymerase and water. 
45 µl of this PCR reaction mixture was prepared (table 3.5). 
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Table 3.5 : Volumes of components used in PCR for detection of mtrR gene 
Component Volume (µl) 
Distilled Water (dH2O) 36 
PCR Buffer 5 
MgCh 1 
DNTP 0.5 
Primer CEL # 1 1 
Primer KH9 # 3 1 
Taq Polymerase 0.5 
Total 45 
Five microlitres of template N gonorrhoeae DNA was added to the PCR reaction 
mixture. The final volume of the reaction mixture was 50 µl. 
3.4.4.2 PCR Cycling Conditions : 
The reaction mixture was amplified in a Gene Amp PCR system 9700 thermocycler 
under the following conditions : initial denaturation at 94°C for 3 minutes, followed 
by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 65°C for 15 seconds 
and extension at 72°C for 5 minutes. Final extension was at 72°C for 5 minutes and 
then incubation at 4°C until use. 
3.4.4.3 PCR Primers and Controls : 
Gonococcal strain FA 19 was used as a positive control while distilled water was used 
as a negative control. 
The following primers were used to detect the mtr R gene 
CEL # 1: 5'-GAC AAT GTT CAT GCG ATG ATA GG-3' 
KH9 # 3: 5'-GAC GAC AGT GCC AAT GCA ACG-3' (Hagman et al., 1995) 
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3.4.4.4 Electrophoresis of PCR Products : 
Ten microlitres of the amplified PCR products were electrophoresed through a 2% 
agarose gel submerged in 0.5X TBE buffer. A 100 bp DNA marker was used. 
Visualisation of the DNA bands was carried out in the Gene Genius Bioimaging 
System after ethidiurn bromide staining. A 1087 bp product was expected. 
3.5 Sequencing 
The 16S rRNA PCR products were sequenced to determine the presence or absence of 
a mutation in the 16S rRNA which commonly causes spectinomycin resistance as 
well as in the mtrR gene of the mtrRCDE efflux pump. 
Sequencing was performed by Inqaba Biotech using the Genetic Analysis System 
SCE2410 with 24 capillaries from SpectruMedix LLC in Pennsylvania, USA. For the 
reactions the BigDye version 3.1 Dye Terminator Cycle Sequencing kit from Applied 
Biosystems was used. 
The software program used for the analysis of the sequences obtained was Chromas 
2.31. BioEdit version 7.0.5.2 is a biological sequence alignment editor that was used 
to compile the sequences. The sequences were subsequently aligned using MAFFT 
which is a software program that uses a variety of methods to align multiple amino 
acid or nucleotide sequences (Katoh, 2006). 
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3.5.1 Sequencing of the 16S rRNA 
Following the amplification of the 16S rRNA region of the N gonorrhoeae isolates 
via PCR, the products were sequenced to determine if the 01064 - C1192 mutation was 
present in the isolates. Primers F980 (5'-CTT ACC TGG TCT TGA CA-3') and 
R1353 (5'- CGA TTA CTA GCG ATT CC-3') were used in the sequencing reactions. 
3.5.2 Sequencing of the mtrR Gene 
The mtrR gene was also sequenced to detect potential mutations in the gene. This was 
done using primers CEL # 1 (5'-GAC AAT GTT CAT GCG ATG ATA GG-3') and 




4.1 MIC Results 
Table 4.1 : Minimum Inhibitory Concentration (MIC) of Spectinomycin amongst 
Neisseria gonorrhoeae isolates obtained in 2000 and 2004 
Year 
MIC (mg/L) 
8 16 32 64 128 
2000 
1 10 10 3 1 
(n == 25) 
-
2004 
2 11 15 
(n == 28) 
- - -
A comparison of the MI Cs from 2000 with that of 2004 shows a shift to the right. 
Amongst the 2004 set of isolates 60% show MIC values of 64 mg/L, which is above 
the breakpoint for susceptibility. 
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4.2 PCR Results 
4.2.1 Detection of the aadA gene 
Gels 1 and 2 represent results for all 28 N gonorrhoeae samples collected in 2004. 
Gel 1 
18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 M 
284 bp 
Gel2 
14 13 12 11 10 9 8 7 6 5 4 3 2 I M 
284 bp 








In gels 1 and 2, lane M contains a 100 bp DNA marker. With reference to gel 1, lanes 
1 to 16 contain PCR amplified N gonorrhoeae DNA. Lane 17 contains a positive 
control (E. coli (C600, pHP 450), known to contain the aad.A gene) and lane 18 
contains a negative control (water). The only band to form was that of the positive 
control at 284 bp. The absence of bands on the gel indicates the absence of the aad.A 
gene in the N gonorrhoeae samples. The positive control band in lane 17 is intense. 
The negative control lane remained blank. 
Lanes 1 to 12 in gel 2 contain PCR amplified N gonorrhoeae DNA while lane 13 
contains a positive control (E. coli (C600, pHP 450), known to contain the aad.A 
gene) and lane 14 contains a negative control (water). The results are identical to gel 1 
with the only band to form being that of the intense positive control band at 284 bp, 
indicating the absence of the aad.A gene in these samples as well as the absence of 
plasmid mediated resistance. Since the results indicate that the aad.A gene is absent in 
these N gonorrhoeae isolates, a region of the 16S rRNA was detected and sequenced 
to confirm the presence or absence of a mutation which is commonly responsible for 
spectinomycin resistance. 
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4.2.2 Detection of 16S rRNA 
PCR for the detection of 16S rRNA was carried out on samples collected in 2000 and 
2004. 
Gel 1 
18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 I M 
Gel2 
12 11 IO 9 8 7 6 5 4 3 2 I M 
373 bp 








Lanes M, in gels 1 and 2 contain a 100 bp DNA ladder as a marker. Gel 1 contains N 
gonorrhoeae DNA from lanes 1 to 1 7, while lane 18 contains a negative control 
(water). Lanes 1 to 11 in gel 2 contain N gonorrhoeae DNA and lane 12 contains a 
negative control (water). Both negative control lanes (i.e. lane 18 in gel 1 and lane 12 
in gel 2) remained empty. Some bands that formed at the expected 373 bp were 
intense but not all the bands were clearly visible. As a result of this, a nested PCR was 
performed on the samples that gave faint bands. 
4.2.3 Nested PCR for Detection of 16S rRNA 
M 2 3 4 5 6 7 
400 bp 
Figure 4.3 : Intense DNA bands present after nested PCR experiment 
Lane M contains a 100 bp DNA marker. Lanes 1 to 6 contain N gonorrhoeae DNA 
that has been amplified twice, while lane 7 contains a negative control (water). The 
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bands which formed at 373 bp are significantly more intense, this is due to the double 
amplification of the DNA, as opposed to the faint bands obtained with only a single 
amplification of the DNA (figure 4.2, gel 1, lane 16 and gel 2, lanes 2 to 6). 
4.2.4 Detection of mtrR gene 
PCR for the detection of the mtrR gene was carried out on samples collected in 2000 
and 2004. 
21 20 19 18 17 16 15 14 I 3 I 2 11 IO 9 8 76 54 32 1M 
1087 bp 
Figure 4.4 : Electrophoresis of PCR products for the detection of the mtrR gene 
1500 bp 
1000 bp 
Lane M contains a 100 bp DNA marker while lanes 1 to 19 contain N gonorrhoeae 
DNA. The positive control (FA 19) was run in lane 20 and a negative control (water) 
in lane 21. All the samples carried the mtrR gene as is indicated by the formation of 
bands at 1087 bp in all the lanes containing N gonorrhoeae DNA. These PCR 
products were sequenced to determine whether mutations exist in the mtrR gene. 
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4.3 Sequencing Results 
4.3.1 Sequencing of the 16S rRNA 
Sequencing and analysis of all 53 N gonorrhoeae isolates revealed that no mutation 
was present in any of the isolates. The region of the 16S rRNA of each isolate which 
usually contains the G1064-C1 192 mutation was compared to the same region of a fully 
susceptible N gonorrhoeae strain from the Genbank database. No mutations were 
detected (see appendix 6 for sequences). 
4.3.2 Sequencing of the mtrR Gene 
Although some mutations were present in the mtrR gene, the phylogenetic analysis 
revealed that there were no distinct clusters which could group isolates according to 





Sexually transmitted infections are a major health concern in KwaZulu Natal. The 
prevalence of discharge causing organisms has remained constant despite the 
introduction of syndrome management in 1995 (Moodley et al., 2001). The lack of 
rapid and reliable point-of-care tests coupled with poor symptom recognition amongst 
patients and the increasing prevalence of organisms resistant to recommended 
antimicrobials, has made the treatment of sexually transmitted infections a challenge. 
Neisseria gonorrhoeae has developed resistance mechanisms against all previously 
prescribed and most currently recommended antimicrobial agents. The development 
of resistance has been reported throughout the world (WHO, 2001) including KZN, 
South Africa (Chenia et al., 1997; Moodley et al., 2001). 
Local reports have highlighted the increase in MIC values of first line antimicrobial 
agents like penicillin, tetracycline, ciprofloxacin and ceftriaxone against N 
gonorrhoeae (Moodley et al., 2001). This has led to scientists looking at alternative 
agents for the management of gonorrhoea. Spectinomycin which was classically used 
as part of syndromic management for vaginal discharge in pregnant women is one 
such agent. However there have been reports of increasing MI Cs to spectinomycin as 
well (Moodley et al., 2001; Moodley et al., 2006). This suggests that using 
spectinomycin as an alternative treatment agent may not be feasible. 
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One of two possible mechanisms is thought to be responsible for the increasing MI Cs 
of spectinomycin viz.: an antibiotic modifying enzyme encoded for by the aadA gene 
and a chromosomal mutation in the l 6S rRNA. N. gonorrhoeae has developed a 
number of chromosomally and plasmid mediated mechanisms of resistance to various 
antimicrobial agents ranging from the alteration of the antibiotics target site to the 
acquisition of new DNA (Tapsall, 2001). The presence of the aadA gene on R­
plasmids has been shown to be responsible for spectinomycin resistance in many 
Gram negative organisms (Clark et al., 1999). This has not been shown in N. 
gonorrhoeae to date. Researchers have speculated that this may also occur with N. 
gonorrhoeae acquiring a similar mechanism of resistance (Johnson and Morse, 1987). 
The acquisition of this gene would adversely affect the treatment of infection with N. 
gonorhoeae, as plasmid mediated resistance has the potential to spread rapidly 
(Tapsall, 2001). 
It has been shown that resistance due to the ribosomal mutation is a one step event 
(Tapsall, 2001). Since our MICs show an incremental rise, we postulated that the 
resistance is due to a modifying enzyme. PCR experiments were carried out to detect 
the presence or absence of the aadA gene amongst our N. gonorrhoeae isolates. 
Subsequent to optimisation, electrophoresis revealed that the aadA gene was 
completely absent in every isolate. The presence and intensity of the positive control 
band indicated that the PCR reaction mixture and conditions were all optimal. It can 
therefore be stated that the increase in MICs observed amongst N. gonorrhoeae 
isolates in Durban is not at ributable to the antibiotic modifying enzyme which is 
encoded by the aadA gene. 
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A very common mechanism of spectinomycin resistance in N gonorrhoeae is the 16S 
rRNA mutation which results in the alteration of the spectinomycin binding site 
(Johanson and Hughes, 1995). Although this has been linked to resistance as a result 
of a one step mutation, it is the only other reported mechanism and we therefore 
studied this. In order to establish whether the isolates in this study carried the 
mutation, a PCR was carried out to amplify the 16S rRNA of each isolate. 
Subsequently, the 373 bp product was sequenced to determine the presence or 
absence of the mutation. 
A comparison of the sequence of the fully susceptible strain contained in Genbank 
with the local fully susceptible isolates as well as those with decreased susceptibility 
did not reveal any differences. The absence of the G1064-C1192 mutation in our study 
isolates suggests that this mutation does not play a role in the increase in MICs to 
spectinomycin observed. It also suggests that another binding site for spectinomycin 
may exist, one which has not as yet been characterised. 
In 1995, Johanson and Hughes showed the presence of another chromosomal 
mutation, C1O66U, which also causes spectinomycin resistance in E. coli (Johanson 
and Hughes, 1995). It is, however, unlikely that this mutation is the cause for the 
increasing MICs seen locally. Whilst the mutation described by Johanson and 
Hughes, 1995 is located in the vicinity of G1064-C1192, the sequencing of our isolates 
did not reveal any changes in this region. 
Another possibility for the increase in MICs to spectinomycin amongst our isolates 
includes a decrease in the concentration of the drug that reaches the target. This could 
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be the result of efflux pumps which extrude the drug (Powell, 2000). Although no 
efflux pumps have specifically been defined for spectinomycin in N gonorrhoeae, 
there are a number of multidrug efflux systems present in other Gram negative 
bacteria which cause resistance to various antimicrobial agents (V akulenko et al., 
2003). 
The existence of the mtr RCDE efflux pump in N gonorrhoeae organisms has 
contributed to the development of resistance to a range of antimicrobial agents. 
Previous studies have shown that mutations in the mtrR gene of this efflux system 
result in decreased repression of the mtrCDE genes and an over expression of the 
pump (Hagman et al., 1995; Veal et al., 1998; Grkovic et al., 2002). Efflux pumps 
have been described locally in N gonorrhoeae for ciprofloxacin (Abbai, 2005). It is 
for this reason that the mtrR gene was focused on for this investigation. 
PCR was done to amplify the mtrR gene, which was detected in all samples. These 
PCR products were then sequenced to determine if mutations existed in the gene. 
Although mutations did exist in the mtrR gene, phylogenetic analysis and grouping of 
the samples revealed that no correlation existed between the mutations carried by the 
mtrR gene and the MI Cs of the study isolates. 
This does not completely rule out the mtrRCDE efflux pump as a potential resistance 
mechanism as it is possible that the drug could be pumped out at varying efflux rates 
or in different amounts. Further investigation will be required to determine whether 
this is the case. 
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Other possibilities include the synthesis of resistant metabolic pathways in which 
pathways are altered to counteract the effect of the drug or the failure to metabolise 
the drug by the bacteria resulting in resistance (Powell, 2000). These mechanisms of 
resistance have been described for aminoglycosides, a drug class that is closely 
related to spectinomycin (Vakulenko et al., 2003). 
According to Powell (2000), there are five major categories of acquired antimicrobial 
resistance. Enzyme inactivation of a drug is one such mechanism (Powell, 2000). 
Although the aad.A gene, which mediates spectinomycin resistance via the ANT(3) 
enzyme, was absent in the samples tested in this investigation, it does not completely 
rule out this mechanism. A study conducted in Denmark in 1999 revealed the 
sequence of a new gene in the aad.A gene cassette. The aad.A5 gene is present in both 
Gram positive and Gram negative organisms and mediates resistance to 
spectinomycin and streptomycin (Sandvang, 1999). Another study carried out in 
Switzerland in 1981 investigated the presence of aminocyclitol modifying enzyme 
genes in the chromosomal DNA of S. aureus and no evidence for the presence of 




In order to curb the growing epidemic of gonorrhoea in South Africa and around the 
world, effective antimicrobial treatment must complement the other components of 
syndromic management. Unfortunately, N gonorrhoeae is notorious for constantly 
changing its genetic makeup and rapidly developing resistance mechanisms to drugs 
recommended for its treatment. The study of antimicrobial resistance mechanisms 
may help to detect early changes in the microbial makeup before clinical resistance 
occurs. It also plays a role in guiding the development of new antimicrobial agents. 
The mechanism associated with the increase in MICs of N gonorrhoeae to 
spectinomycin was shown not to be related to the antibiotic modifying enzyme 
encoded for by the aad.A gene or the 16S rRNA mutation. Other undescribed 
antibiotic modifying enzymes may however play a role in the increase in MICs 
observed. Although sequencing of the mtrR gene did not reveal any MIC clusters, the 
mtrRCDE efflux pump is still a potential mechanism that could confer resistance to 
spectinomycin in N gonorrhoeae. Further investigation looking at intracellular 
concentration of this drug to determine the extent of the role of the efflux pump is 
warranted. Other possible mechanisms that could infer resistance include the 
synthesis of resistant metabolic pathways or failure of the organism to metabolise the 
drug. 
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Increasing resistance of microbes to newer and more sophisticated antimicrobial 
agents have led policy makers to look at alternative agents for the treatment of 
infections. Unfortunately, development of antimicrobials with novel mechanisms of 
action have lagged behind the development of resistance mechanisms in microbes. As 
a result, older agents that have long been shelved are now making their appearance in 
the clinical arena. Spectinomycin is an old antimicrobial agent that is now re­
emerging as an alternative for treatment of N gonorrhoeae. However not much work 
has been done on this drug and its effect on N gonorrhoeae. 
The results of this study show that the resistance mechanisms classically related to 
spectinomycin and other microbes are not present in local N gonorrhoeae isolates 
displaying increasing MI Cs to the drug. Alternative mechanisms of resistance need to 




Abbai, N. 2005. A Novel Mechanism Conferring Decreased Susceptibility to 
Multiple Antibiotics in Neisseria gonorrhoeae Isolates from Kwa-Zulu Natal. 
Unpublished. 
Alary, M. 1997. Gonorrhoea : Epidemiology and Control Strategies. The 
Canadian Journal of Human Sexuality 6 (2) : 151 - 159. 
Apea - Kubi, K.A., S. Yamaguchi, B. Sakyi, T. Kisimoto, D. Ofori-Adjei and 
T. Hagiwara. 2004. Neisseria gonorrhoeae, Chlamydia trachomatis and
Treponema pallidum Infection in Antenatal and Gynecological Patients at Karle­
Bu Teaching Hospital, Ghana. (Abstract) Japanese Journal of Infectious Disease 
57: 253 - 256 
Arreaza, L., C. Salcedo, B. Alcala, S. Berron, E. Martin and J.A. Vazquez. 
2003. Antibiotic Resistance of Neisseria gonorrhoeae in Spain : Trends Over the 
Last Two Decades. Journal of Antimicrobial Chemotherapy 51: 153 - 156. 
Bala, M., K. Ray and S. Salhan. 2005. First Case of Spectinomycin Resistant 
Nesseria gonorrhoeae Isolate in New Delhi, India. Sexually Transmitted 
Infections 81: 186- 187. 
75 
Barclay, L. (Centers for Disease Control and Prevention (USA)). 2007. CDC 
Issues New Treatment Recommendations for Gonorrhea. Morbidity and Mortality 
Weekly Report 56 : 332 - 336. 
Belda Jr., W., L.F. De Goes Siqueira, M.M.S. Nico and L.J. Fagundes. 2002. 
Activity of Five Antimicrobial Agents In Vitro against Neisseria gonorrhoeae. An 
bras Dermatol 77 (6): 661 - 667. 
Boslego, J.W., E.C. Tramont, E.T. Takafuji, B.M. Diniega, B.S. Mitchell, 
J.W. Small, W.N. Khan and D.C. Stein. 1986. Effect of Spectinomycin Use on 
the Prevalence of Spectinomycin-Resistant and of Penicillinase-Producing 
Neisseria gonorrhoeae. The New England Journal of Medicine 317 (5) : 272 -
277. 
Brink, M.F., G. Brink, M.P. Verbeet and H.A. De Boer. 1994. Spectinomycin 
Interacts Specifically With the Residues G1064 and C11n in the 16S rRNA, 
Thereby Potentially Freezing This Molecule Into an Inactive Conformation. 
Nucleic Acids Research 22 (3) : 325 - 331. 
Bryan, L.E. 1998. General Mechanisms of Resistance to Antibiotics. Journal of 
Antimicrobial Chemotherapy 22: 1 -15. 
Chalkley, L.J., M.N. Janse Van Rensburg, P.C. Mathee, C.A. Ison and P.L 
Botha. 1997. Plasmid Analysis of Neisseria gonorrhoeae Isolates and 
76 
Dissemination of tetM Genes in Southern Africa 1993 - 1995. Journal of 
Antimicrobial Chemptherapy 40 : 817 - 822. 
Cheng, D.S.F. 1989. Gonorrhea, Pg 58 - 69. In L.C. Parish and F. Gschnait (Ed.), 
Sexually Transmitted Diseases : A Guide for Clinicians, Springer-Verlag , New 
York, USA. 
Chenia H.Y., B. Pillay, A.A. Hoosen and D. Pillay. 1997. Antibiotic 
Susceptibility Patterns and Plasmid Profiles of Penicillinase-Producing Neisseria 
gonorrhoeae Strains in Durban, South Africa, 1990 - 1993. Journal of the 
American Sexually Transmitted Disease Association 24 (1) : 18 - 22. 
Clarke, N.C., 0. Olsvik, J.M. Swenson, C.A Spiegel and F.C. Tenover. 1999. 
Detection of a Streptomycin/Spectinomycin Adenyltransferase Gene (aadA) in 
Enterococcus faecalis. Antimicrobial Agents and Chemotherapy 43 (1) : 157 -
160. 
Conte Jr., J.E. and S.L. Barriere. 1992. Manual of Antibiotics and Infectious 
Disease, Pg 38 - 45, 129 - 141. Lea and Febiger, USA. 
Ehret, J.M., L.J. Nims and F.N. Judson. 1995. A Clinical Isolate of Neisseria 
gonorrhoeae With In Vitro Resistance to Erythromycin and Decreased 
Susceptibility to Azithromycin. Sexually Transmitted Diseases 23 : 270 - 272. 
77 
Freeman, B.A. 1985. Burrows Textbook of Microbiology, Pg 414 - 421. W.B. 
Saunders Company, Philadelphia, USA. 
Gale, E.F., E. Cundliffe, P.E. Reynolds, M.H. Richmond, M.J. Waring. 1981. 
The Molecular Basis of Antibiotic Action. John Wiley and Sons, London. 
Galimand, M., G. Gerbaud and P. Courvalin. 2000. Spectinomycin Resistance 
in Neisseria spp. Due to Mutations in 16S rRNA. Antimicrobial Agents and 
Chemotherapy 44 (5) : 1365 -1366. 
Grkovic, S., M.H. Brown and R.A. Skurray. 2002. Regulation of Bacterial 
Drug Efflux Systems. Microbiology and Molecular Biology Reviews 66 (4) : 671 
-701.
Hagman, K.E., W. Pan, B.G. Spratt, J.T. Balthazar, R.C. Judd and W.M. 
Shafer. 1995. Resistance of Neisseria gonorrhoeae to Antimicrobial Hydrophobic 
Agents is Modulated by the mtrRCDE Efflux System. Microbiology 141 : 611 -
622. 
Heckels, J.E. 1978. The Surface Properties of Neisseria gonorrhoeae : 
Topographical Distribution of the Outer Membrane Protein Antigens. Journal of 
General Microbiology 108: 213 -219. 
78 
Heritage, J. 2006, revision date. What Causes Antibiotic Resistance in Bacteria? 
http://www.bmb.leeds.ac.uk/mbiology/ug/ugteach/icu8/antibiotics/resistance/resn 
otes.html 
Hu, M., S. Nandi, C. Davies and R.A. Nicholas. 2005. High-Level 
Chromosomally Mediated Tetracycline Resistance in Neisseria gonorrhoeae 
Results from a Point Mutation in the rpsJ Gene Encoding Ribosomal Protein S 10 
in Combination with the mtrR and penB Resistance Determinants. Antimicrobial 
Agents and Chemotherapy 49 (10) : 4327 - 4334. 
Ison, C.A., J.W. Mouton, K. Jones, K.A. Fenton and D.M. Livermore. 2004. 
Which Cephalosporin for Gonorrhoea? Sexually Transmitted Infections 80: 386 -
388. 
Johanson, U. and D. Hughes. 1995. A new Mutation in 16S rRNA of 
Escherichia coli Conferring Spectinomycin Resistance. Nucleic Acids Research 
23 (3): 464 -466. 
Johnson S.R. and S.A. Morse. 1988. Antibiotic Resistance in Neisseria 
gonorrhoeae : Genetics and Mechanisms of Resistance. Sexually Transmitted 
Diseases 15 (4) : 217 - 224. 
Katoh, K. 2005.
u.ac.jp/mafft/software/
MAFFT version 5.8. 
79 
http://align.bmr.kyushu-
Kayser, F.H., F. Hornberger and M. Devaud. 1981. Aminocyclitol-Modifying 
Enzymes Specified by Chromosomal Genes in Staphylococcus aureus. 
Antmicrobial Agents and Chemotherapy 19 (5): 766- 772. 
Knapp, J.S., K.K. Fox, D.L. Trees and W.L. Whittington. 1997. 
Fluoroquinolone Resistance in Neisseria gonorrhoeae. Emerging Infectious 
Diseaes 3 (1) : 33 - 39. 
Lawung, R., A. Buatiang, T. Jittawoutipoka, S. Rittiroongrad and V. 
Prachayasittikul. 2005. Increasing Trend of Multiple Resistance and Genomic 
Mobility of Neisseria gonorrhoeae to Penicillin and Quinolone. EXCLI Journal 4 
:130-140. 
Li, G., C. Qun and W. Shengchun. 2000. Resistance of Neisseria gonorrhoeae 
Epidemic Strains to Antibiotics : Report of Resistant Isolates and Surveillance in 
Zhanjiang, China : 1998 to 1999. Sexually Transmitted Diseases 27 (2) : 115 -
118. 
Mascaretti, 0. 2003. Bacteria Versus Antimicrobial Agents An Integrated 
Approach, Pg: 149. ASM Press, USA. 
Maness, M.J., G.C. Foster and P.F. Sparling. 1974. Ribosomal Resistance to 
Streptomycin and Spectinomycin in Neisseria gonorrhoeae. Journal of 
Bacteriology 120 (3): 1293 -1299. 
80 
Matsuoka, L.Y. 1989. History, Pg 3 - 6. In L.C. Parish and F. Gschnait (Ed.), 
Sexually Transmitted Diseases : A Guide for Clinicians, Springer-Verlag , New 
York, USA. 
Medline. 1993, revision date. Drug Information 
http://www.nlm.nih.gov/medlinepl us/ druginfo/uspdi/20253 0 .html 
Spectinomycin. 
Moodley, P., C. Pillay, R. Goga, A.B.M. Kharsany amd A.W. Sturm. 2001. 
Evolution in the Trends of Antimicrobial Resistance in Neisseria gonorrhoeae 
Isolated in Durban Over a 5 Year Period : Impact on the Introduction of 
Syndromic Management. Journal of Antimicrobial Chemotherapy 48: 853 - 859. 
Moodley, P., I.M.C Martin, C.A. Ison and A.W. Sturm. 2002a. Typing of 
Neisseria gonorrhoeae Reveals Rapid Reinfection in Rural South Africa. Journal 
of Clinical Microbiology 40 (12) : 4567 - 4570. 
Moodley, P., D. Wilkinson, C. Connolly and A.W. Sturm. 2002b. Influence of 
HIV-1 Co-infection on Effective Management of Abnormal Vaginal Discharge. 
Sexually Transmitted Diseases 30 (1) : 1 - 5. 
Moodley P., I.M.C. Martin, K. Pillay, C.A. Ison and A.W. Sturm. 2006. 
Molecular Epidemiology of Recently Emergent Ciprofloxacin-Resistant Neisseria 
gonorrhoeae in South Africa. Sexually Transmitted Diseases 33 (6) : 357 - 360. 
81 
Morello, J.A. and M. Bohnhoff. 1980. Neisseria and Branhamella, Pg 111 -
122. In E.H. Lennette, A. Balows, W.J. Hausler Jr. and J.P. Truant (Ed.), Manual
of Clinical Microbiology, 3rd ed. American Society for Microbiology,
Washington, USA. 
National Committee for Clinical and Laboratory Standards. 1999. 
Performance Standard for Antimicrobial Susceptibility Testing : Ninth Informal 
Supplement M2 - A6. NCCLS, Villanova, PA. 
Ng, L.K., I. Martin, G. Liu and L. Bryden. 2002. Mutation in 23S rRNA 
Associated With Macrolide Resistance in Neisseria gonorrhoeae. Antimicrobial 
Agents and Chemotherapy 46 (9) : 3020 - 3025. 
Nikiado, H. 1994. Prevention of Drug Access to Bacterial Targets : Permeability 
Barriers and Active Efflux. Science 264 : 382 - 388. 
Oates J.K. and G.W. Csonka. 1990. Gonorrhoea, Pg : 209 - 220. In G.W. 
Csonka and J.K. Oates (Ed.), Sexually Transmitted Diseases, A Textbook of 
Genitourinary Medicine, Bailliere Tindall, London, UK. 
PeaceHealth. 2006. Fitz-Hugh-Curtis Syndrome. http://www.peacehealth.org/ 
kbase/nord/nord945 .htm 
82 
Powell W.J. 2000. Molecular Mechanisms of Antimicrobial Resistance, 
Technical Report #14, http://www.foodsafetynetwork.ca/animal/ab-res-ppr­
wjp.htm 
Quesnel, L.B. and A.D. Russell. 1983. Introduction, Pg: 6 - 13. In A.D. Russell 
and L.B. Quesnel (Ed.), Antibiotics : Assessment of Antimicrobial Activity and 
Resistance, Academic Press, Florida, USA. 
Rahman, M., Z. Sultan, S. Monira, A. Alam, K. Nessa, S. Islam, S. Nahar, 
S.A. Waris, S.A. Khan, J. Bogaerts, N. Islam and J. Albert. 2002. 
Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolated in Bangladesh 
(1997 to 1999) : Rapid Shift to Fluoroquinolone Resistance. Journal of Clinical 
Microbiology 40 (6): 2037 - 2040. 
Ram, S. and P.A. Rice. 2001. Gonococcal Infections, Pg : 435 - 438. In S. Faro 
and D.E. Cooper (Ed.), Infectious Diseases in Women, W.B. Saunders Company, 
Philadelphia, USA. 
Read, D. 2000. Use of Antibiotic Resistance Marker Genes in Genetically 
Modified Organisms. Environmental Risk Management Authority, New Zealand. 
Robertson, D.H.H., A. McMillan and H. Young. 1989. Clinical Practice in 
Sexually Transmissible Diseases, Pg 204 - 223. Churchill-Livingstone, London, 
UK. 
83 
Ropp, P.A., M. Hu, M. Olesky and R.A. Nicolas. 2001. Mutations inponA, the 
Gene Encoding Penicillin-Binding Protein 1, and a Novel Locus, penC, Are 
Required for High-Level Chromosomally Mediated Penicillin Resistance in 
Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy 46 (3) : 769 -
777. 
Ropp, P.A. and R.A. Nicholas. 1997. Cloning and Characterization of the ponA 
Gene Encoding Penicillin-Binding Protein 1 from Neisseria gonorrhoeae and 
Neisseria meningitidis. Journal of Bacteriology 179 (8) : 2783 - 2787. 
Rouquette-Loughlin, C., I. Stojiljkovic, T. Hrobowski, J.T. Balthazar and 
W.M. Shafer. 2002. Inducible, But Not Constitutive, Resistance of Gonococci to
Hydrophobic Agents Due to the MtrC-MtrD-MtrE Efflux Pump Requires TonB­
ExbB-ExbD Proteins. Antimicrobial Agents and Chemotherapy 46 (2): 561 -565. 
Russo, M.E. and M.I.B. Thompson. 1984. Pharmacology of Drugs Used in 
Venerology, Pg : 898 - 905. In K.K. Holmes, P.A. Mardh, P.F. Sparling and P.J. 
Weisner (Ed.), Sexually Transmitted Diseases, McGraw - Hill Book Company, 
USA. 
Salam M.A., I. Ahmed and Q.R. Sultan. 2005. Increasing Pattern of Antibiotic 
Resistance in Neisseria gonorrhoeae. Pakistan Journal of Medical Science 21 (2) 
: 206-209. 
84 
Sandvang, D. 1999. Novel Streptomycin and Spectinomycin Resistance Genes as 
a Gene Cassette within a Class 1 Integron Isolated from Escherichia coli. 
Antimicrobial Agents and Chemotherapy 43 (12): 3036 - 3038 
Schwebke J.R., W. Whittington, R.J. Rice, H.H. Handsfield, J. Hale and K.K. 
Holmes. 1995. Trends in Susceptibility of Neisseria gonorrhoeae to Ceftriaxone 
from 1985 through 1991. Antimicrobial Agents and Chemotherapy 39 ( 4) : 917 -
920. 
Schweizer, H.P. 2003. Efflux as a Mechanism of Resistance to Antimicrobials in 
Pseudomonas aeruginosa and Related Bacteria : Unanswered Questions. Genetic 
and Molecular Research 2 (1): 48 - 62. 
Shigemura, K., H. Okada, T. Shirakawa, K. Tanaka, S. Arakawa, S. 
Kinoshita, A. Gotoh and S. Kamidono. 2004. Susceptibilities of Neisseria 
gonorrhoeae to Fluoroquinolones and Other Antimicrobial Agents in Hyogo and 
Osaka, Japan. Sexually Transmitted Infections 80 : 105 - 107. 
Sturm, P.D.J., P. Moodley, N. Khan, S. Ebrahim, K. Govender, C. Connolly 
and A. W. Sturm. 2004. Aetiology of Male Urethritis in Patients Recruited From 
a Population With a High HIV Prevalence. International Journal of Antimicrobial 
Agents 24S (2004) : S8 - S 14. 
Swanson, J. and L. W. Meyer. 1984. Biology of Bacterial, Chlamydia! and 
Mycoplasmal Infections, Pg: 198. In K.K. Holmes, P.A. Mardh, P.F. Sparling and 
85 
P.J. Weisner (Ed.), Sexually Transmitted Diseases, McGraw - Hill Book 
Company, USA. 
Tanaka, M., H. Nakayama, M. Haraoka, T. Saika, I. Kobayashi and S. Naito. 
2000. Antimicrobial Resistance of Neisseria gonorrhoeae and High Prevalence of 
Ciprofloxacin-Resistant Isolates in Japan, 1993 to 1998. Journal of Clinical 
Microbiology 38 (2): 521 -525. 
Tapsall, J. 2001. Antimicrobial Resistance in Neisseria gonorrhoeae. WHO 
Collaborating Centre for STD and HIV, Sydney, Australia. Pg: 14-26. 
Todar, K. 2004. The Pathogenic Neisseriae. In K. Todar, Textbook of 
Bacteriology, http ://textbookofbacterio logy. net/medical .html 
Vakulenko, S.B. and S. Mobashery. 2003. Versatility of Aminoglycosides and 
Prospects for Their Future. Clinical Microbiology Review 16 (3) : 430 - 450. 
Veal, W.L., A. Yellen, J.T. Balthazar, W. Pan, B.G. Spratt and W.M. Shafer. 
1998. Loss-of-Function Mutations in the mfr Efflux System of Neisseria 
gonorrhoeae. Microbiology 144: 621 -627. 
Veal, W.L., R.A. Nicholas and W.M. Shafer. 2002. Overexpression of the 
MtrC-MtrD-MtrE Efflux Pump Due to an mtrR Mutation is Required for 
Chromosomally Mediated Penicillin Resistance in Neisseria gonorrhoeae. 
Journal of Bacteriology 184 (20) : 5619 - 5624. 
86 
Verster, B. and S. Douthwaite. 2001. Macrolide Resistance Conferred by Base 
Substitutions in 23S rRNA. Antimicrobial Agents and Chemotherapy 45 (1) : 1 -
12. 
Webber, M.A. and L.J.V. Piddock. 2003. The Importance of Efflux Pumps in 
Bacterial Antibiotic Resistance. Journal of Antimicrobial Chemotherapy 51 : 9 -
11. 
Whittington, W., C. Ison and S. Thompson. 1994. Gonorrhea, Pg : 100 - 117. 
In S.A. Morse, A.A. Moreland and K.K. Holmes (Ed.), Atlas of Sexually 
Transmitted Diseases and AIDS, 2nd ed. Mosby, St Louis. 
World Health Organisation. Global Prevalence and Incidence of Selected 
Curable Sexually Transmitted Infections Overview and Estimates. 2001. Geneva. 
Wilson, J. 2000. Clinical Microbiology : An Introduction for Healthcare 
Professionals, Pg: 9; 89 - 95. Baillere-Tindall, UK. 
Workowski, K.A., W.C. Levine and J.N. Wasserheit. 2002. U.S. Centres for 
Disease Control and Prevention Guidelines for the Treatment of Sexually 
Transmitted Diseases : An Opportunity to Unify Clinical and Public Health 
Practice. Academia and Clinic 137 (4) : 255 - 262. 
87 
Zheng, H.P., W.L. Cao, X.Z. Wu and L.G. Yang. 2003. Antimicrobial 
Susceptibilty of Neisseria gonorrhoeae Strains Isolated in Guangzhou, China. 




Appendix 1 : Preparation of Culture Media 
1.1 New York City Agar Plates: 












The GC agar base was dissolved in deionised water and autoclaved at 120°C for 15 
minutes. The solution was then cooled to 55°C in a waterbath. The LCAT and yeast 
autolysate were subsequently added. Sapopnin was added to the horse blood in order 
to lyse it. Finally the lysed horse blood was added to the rest of the media solution, 
mixed well and aliquoted into Petri dishes. 
1.2 GC Storage Broth : 






Tryptic soy broth and glycerol were mixed, added to deionised water and autoclaved 
at 120°C for 15 minutes. The mixture was then cooled, aliquoted into cryovials 
containing sterile glass beads and stored at 2 - 8
°
C until use. 
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Appendix 2 : Inoculation Standard for MIC 
2.1 0.5 McFarland Standard: 
2.1.11 % H2SO4 Solution : 
Concentrated H2SO4 
Water 
The concentrated H2SO4 and deionised water were mixed. 
2.1.2 1 % Ba Ch Solution : 
BaCh.2H2O 
Water 
The BaCh.2H2O and deionised water were mixed. 
1 % H2SO4 Solution 







The 1 % H2SO4 solution and 1 % BaCh solution were mixed well. The tubes were 
sealed and kept in a dark environment. The solution was vortexed thoroughly before 
use. 
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Appendix 3 : Solutions for Agarose Gel Electrophoresis 





EDT A was added to deionised water and stirred vigorously with a magnetic stirrer. 
The pH was adjusted to 8.0 using NaOH pellets. The volume of the solution was 
made up to 1000 ml and autoclaved at 120°C for 15 minutes. 
3.2 SX TBE Buff er Stock Solution (Tris-Cl / Borate EDT A) (pH 8.5) : 
Trisma Base 54 g 
Boric Acid (H3BO3) 





Trisma base and boric acid were dissolved in deionised water. EDT A was added. pH 
was adjusted to 8.5 and the solution autoclaved at l 20°C for 15 minutes. 
3.3 O.SX TBE (Tris-Cl/ Borate EDT A) Buffer : 
5X TBE Buffer Stock Solution 
Water 











Two point five grams of sucrose and 0.025 g of bromophenol blue were added to 
deionised water and mixed. The solution was stored at 4°C. 





Ethidium bromide powder was dissolved in deionised water and stored at 4°C, in the 
dark. 
3.5 2 % Agarose Gel : 
Agarose 




1 µl / ml buffer 
Agarose was added to 0.5X TBE buffer. The solution was boiled and then allowed to 
cool to 70°C at room temperature. Ethidium bromide was added. The solution was 
then thoroughly stirred and poured into the gel racks and a comb placed on one side of 
the gel to form the wells and allowed to set. 
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Appendix 4 : Optimisation of PCR 
The optimisation experiments contained the combination of dNTP and MgCh 
concentrations shown below . 
Table 8.1 : dNTP and MgCh concentrations and volumes for optimisation of PCR 
Concentration Volume (µI) 
dNTP 100 µM 0.5 
MgCh 1.5mM 0 
Set A 2.0mM 1 
2.5 mM 2 
3.0mM 3 
3.5mM 4 
dNTP 200 µM 1.0 
MgCh 1.5mM 0 




dNTP 250 µM 1.25 
MgCh 1.5mM 0 
Set C 2.0mM 1 
2.5mM 2 
3.0mM 3 
3.5 mM 4 
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Table 8.2 : Volumes (µl) of PCR components used for optimisation of aadA gene 
PCR 
PCR Forward Reverse Taq dH20 dNTP MgCh 
Buffer Primer Primer Polymerase 
5 1 1 0.5 32 0.5 0 
5 1 1 0.5 31 0.5 1 
Set A 5 1 1 0.5 30 0.5 2 
5 1 1 0.5 29 0.5 3 
5 1 1 0.5 28 0.5 4 
5 1 1 0.5 31.5 1 0 
5 1 1 0.5 30.5 1 1 
SetB 5 1 1 0.5 29.5 1 2 
5 1 1 0.5 28.5 1 3 
5 1 1 0.5 27.5 1 4 
5 1 1 0.5 31.25 1.25 0 
5 1 1 0.5 30.25 1.25 1 
Set C 5 1 1 0.5 29.25 1.25 2 
5 1 1 0.5 28.25 1.25 3 
5 1 1 0.5 27.25 1.25 4 
Table 8.3 : Volumes (µ1) of PCR components used for optimisation of 16S rRNA 
PCR 
PCR Forward Reverse Taq dH20 DNTP MgCh 
Buffer Primer Primer Polymerase 
10 1 1 1 76.5 0.5 0 
10 1 1 1 75.5 0.5 1 
Set A 10 1 1 1 74.5 0.5 2 
10 1 1 1 73.5 0.5 3 
10 1 1 1 72.5 0.5 4 
10 1 1 1 76 1 0 
10 1 1 1 75 1 1 
SetB 10 1 1 1 74 1 2 
10 1 1 1 73 1 3 
10 1 1 1 72 1 4 
10 1 1 1 75.75 1.25 0 
10 1 1 1 74.75 1.25 1 
Set C 10 1 1 1 73.75 1.25 2 
10 1 1 1 72.75 1.25 3 
10 1 1 1 71.75 1.25 4 
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Appendix 5 : PCR Results 
5.1 Initial Detection of the aadA gene 
21 20 19 18 17 16 15 14 I 3 I 2 11 IO 9 8 7 6 5 4 3 
284 bp 
Figure 8.1 : Electrophoresis gel for the detection of the aadA gene 





Lane M contains a 100 bp DNA marker, while lanes 1 to 18 contain PCR amplified N 
gonorrhoeae DNA. Lanes 19 and 20 contain a positive control (E. coli (C600, pHP 
450), known to contain the aad.A gene) and lane 21 contains a negative control 
(water). As is evident, the only bands to form were those of the positive control and 
were 284 bp in size. Although present, these bands were extremely faint, indicating 
that optimisation was required. The remaining lanes, including the negative control 
lane remained empty. 
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5.2 Optimisation of aadA gene PCR 
65 4321 6543 21 
284 bp 
Figure 8.2 : Optimisation of the aadA gene PCR 




Lane M contains a 100 bp DNA marker. Lanes 1 to 5 in sets A, B and C all contain 
the PCR amplified positive control, E. coli (C600, pHP 450) while lane 6 contains a 
negative control (water). All bands formed were 284 bp in size. The brightest band 
formed in lane 1 of set A. 
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were sequenced. As can be seen, bands formed on the gel at the 3 73 bp mark, as 
expected. The bands were however of varying intensity, this meant that certain bands 
may have been present and not visible to the naked eye, therefore optimisation of the 
PCR reaction mixture was done in order to make sure that all bands that were present 
were visible. The negative control lane remained empty. 
5.4 Optimisation of 16S rRNA PCR 
M12 34 56 1 2 3 4 5 6 1 2 3 4 5 6 
373 bp 
400 bp 
Figure 8.4: Optimisation of the 16S rRNA PCR 
Lane M contains a 100 bp DNA marker. Lane 6 in sets A, B and C all contain a 
negative control (water) and as can be seen, no bands have formed in any of the 
negative control lanes. Lanes 1 to 5 in each set contain the N. gonorrhoeae DNA of 
sample B2, which formed a very light band in the initial PCR that was run (figure 4.5, 
gel 1, lane 2). This experiment was done to determine the PCR reaction mixture that 
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would result in bands of a high intensity. All the bands formed at 373 bp, as expected 
and the brightest band formed in lane 3 of set C. 
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Appendix 6 : Sequencing Results 
6.1 Mutations in mtrR Gene 
Table 8.4 : mtrR gene mutations an MICs for each isolate 




G➔A 594,841, 1226 
Bl 







G➔T 28, 811 
C➔G 565, 1231 
B2 





G➔C 21, 22, 31, 41 
C➔T 24,568, 1231 
T➔A 26,34,812 
A➔G 27,30,40,856 
G➔A 28,594,841, 1029 




T➔C 850, 1229 
A➔C 1234 
B24 G➔C 21, 22 64 
C➔T 23,24,568 
















C➔T 568, 1217, 1220, 1231 64 
C➔A 800 
G➔T 811, 1226 




T➔C 25,34,69,850, 1233 
G➔T 28, 31, 811 
A➔G 30, 856, 1189, 1211, 1224 
A35 
A➔T 33, 1222 64 
T➔G 59, 1221, 1229 
G➔A 395,594,841, 1226 
C➔G 565 
C➔T 568, 1231 
T➔A 812, 1236 
A➔C 30 




A42 C➔G 42,64,565 64 
A➔G 43,856, 1225 
T➔G 46 
G➔A 594,841, 1029, 1226 
C➔A 800 
T➔A 812 
A43 G➔C 22 32 
G➔T 811 









T➔A 812, 1221 










T➔A 812, 1221 
T➔C 1216, 1219 
C➔T 1217, 1220 
G➔A 615, 1226 
C➔A 800 
A 164 G➔T 811 32 
T➔A 812 
A➔G 1173, 1227 
G➔C 22,41 
C➔T 24,568, 1217, 1220 









T➔C 1216, 1219 
G➔C 21,22,28 
C➔T 23,24,808, 1217, 1220 
T➔A 26, 812, 1221 
A➔G 27,856 
B186 
A➔T 29, 1234 
32 
T➔G 433, 1229 
C➔A 800 
G➔T 811, 1226 
G➔A 841 













A➔C 569, 1214 
C➔G 603, 1213 
T➔C 626,850 
A➔T 701 
T➔A 739,812, 1215 
C➔T 808 
G➔C 21,22 
C➔A 23,800, 1220, 1231 
C➔T 24,622,808, 1217 
T➔A 25,26,812, 1221 
A➔T 27,29, 1214, 1230, 1232 
Tl 124 G➔A 28,841, 1226 32 
A➔C 30, 1227 
G➔T 31,811 
T➔C 63,657,665,850, 1216, 1218, 1233 
T➔G 739 
A➔G 747,856, 1141, 1173, 1177, 1224 
G➔A 21,28,471,534, 1083, 1226 
G➔T 22,31,588,602,811 
C➔A 23,480,800 
C➔T 24,462,521,590,608, 1231 
T➔A 25,517, 812, 1236 
Tl 192 
A➔C 27,458,484, 1214, 1232 
16 
A➔T 29,463,593,607, 1225 
A➔G 43,356,466,516, 1227 
C➔G 325,564,565,587,603 
T➔C 358,375, 514, 1215 
T➔G 374,433,523,562 
G➔C 432,563,594,598,601 
G➔C 21, 22, 731 
C➔G 23,42, 798 
C➔A 24,766,800 
T➔A 26,669,777 
A➔T 27,29,33,48, 700,701,724,774 
Tl 189** 




A➔G 36,37,483,505, 707 
T➔G 46,562 
T➔C 51,63,666, 739 
C➔T 581 







G➔T 28, 811 
32 
T➔C 409,657,665,850 
G➔A 448,725,841, 1226 
T➔G 739 
A➔G 747,856, 1227 
C➔A 800 
C➔G 565, 1213, 1231 
C➔T 568 
G➔A 594, 1212 
C➔A 800 
127 072 G➔T 811, 1226 64 
T➔A 812, 1229 
A➔G 1208, 1211 
A➔C 1214, 1230 
T➔C 1215 
G➔C 21, 22, 28, 31 
C➔T 23,32,568 
C➔A 24,800 
127 222 T➔A 26,812 16 












USB213 A➔C 40 16 







G➔C 371, 985 
C➔A 434,800 
C➔G 461 
G➔A 841, 1226 
























G➔A 31, 1226 
C➔A 800 
USB266 G➔T 811 8 
T➔A 812 
A➔G 1225, 1227 
G➔C 21 
G➔A 22,31,448,841, 1226 
C➔G 23 
T➔C 25,26,49,63,850, 1236 
A➔T 27,36,463,466, 1222 
USB312 





T➔G 69,467, 1221 
C➔A 800 
A➔G 856, 1227 
108 
A➔T 29 








































A➔G 856, 1175, 1225 
T➔G 1236 
USB399 C➔A 32,800 16 
A➔T 33,403, 1222 
T➔A 34,402, 812,1215 
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A➔C 40, 1230 
G➔C 62,399 
T➔C 63,850, 1218, 1221 







G➔T 22, 811 
C➔T 24 









USB491 G ➔T 302,487,811, 1226 16 
G➔C 371,425,728 
A➔G 407,856, 1225 
C➔G 427,565,729 
C➔A 800 







A➔C 27 8 
G➔T 28,811,933 
A➔T 29,33,36 
G➔A 31,594,978, 1226 
T➔A 34, 76,812 
A➔G 43,971, 1225, 1227 
C➔G 89,565 
USB553 G➔C 21 4 









T➔C 57,850, 1216, 1219 
G➔A 328,594,841, 1226 





C➔T 568, 1217, 1220 
C➔A 800 
G➔T 811 
T➔A 812, 1221 
A➔T 1232 
T➔A 61, 812 
G➔T 62,306,811 
T➔G 63,69, 76,307 
T➔C 66,850 














USB598 G➔A 21, 81,594 16 
















USB599 G➔A 841, 1226 64 
T➔C 850 





























T➔C 850, 1236 













G➔T 21, 811 











6.2 16S rRNA Sequences : 

































































6.3 mtrR Gene Sequences : 









































































































































































Sample USB 970 
GCCAACGCGGCCGCACGCA-TCGCCTTAGACCAT-AAAAAGCA--TTAT-TTATCCTATC 
TGTC-TGGTTTGATGTA-AAGGGTTTTGCCAATCAACAGGCATTCT--------------
-----------------------TATTTCAGGATAT-AAAAA-CCGCCTGCTTTGATACC 
CGAATGTTCGAACGGGTTGCAAAGCAGGTTATACCTGTTTTCAAAGTTGAGATGCAGTCT 
CAATTTTAT-GGGTTTCATTATACATACACGATTGCACGGAT-AAAAGTCTTTTTTATAA 
T-CCG-CCCTCGTCAAA-CCG-ACCCGGAAACG-AAAACGCCATTATGGAGAAAAA--CC
AAAACCG-AAGCCTTGAAAACCAAAGAACACC-TGATG--C-TTGCCGCCTTGGAAACC­
TTTT----ACCGCAAAGGGATTGCCCGCACCTCGCTC-AACGAAATCGCCCAAG-CCGCC 
GGCGTAAC-GCGCGGCGCGCTCTA-TTGGCATTTCAAAAATAAGGAAGACTTG-TTTGAC 
GCG-TTGTT-CCAACGTAT-CT-GCGACGACATC--G-AAAACTGCATCGCGCAAGATGC 
CGCAGATGCCGAAGGAGGTTC-TTGGACGGTATTCCGCCA-CACGC-TGCTGCAC-TTTT 
TC-GAGCGGCTGCAfl.AGCAACGACATCTACTACAAATTCCACAACAT-CCTGTTTTTAAA 
ATGCGAACACACGGAGCAAAACGCCGCCGTTATCGCCATTGCCCGCAAGCATCAGGCAAT 
C-TGGCGCGAGAAAATTACCGCCGTTTTGACCGAAGCGGTGGAAAATCAGGATTTGGCTG
ACGA-TTTGGA-CAA-GGAAA-CGGCGG--TCATC-TTCATCAAATCGACGTTGGACGGG 
C-TGATTTGGCGT-TGGTTCTCTTCCGGCGAAAGTTTCGATTTGGGCAAAACCGCCCCGC
--GCATCATCGGGATAATGATGGACAACTTGGAAAACCATCCCTGCCTGCGCCGGAAATA 
ATCAAGCCTTGGTAACAATGCCGTCTG-AAACAAACAAACCCTTTCAAAC-GGCATCAAA 
ATGACACAA-AGCATTCTTCTAAAAGA-TACATATTC-----------------------
119 
